<SEC-DOCUMENT>0001140361-24-045002.txt : 20241101
<SEC-HEADER>0001140361-24-045002.hdr.sgml : 20241101
<ACCEPTANCE-DATETIME>20241101160605
ACCESSION NUMBER:		0001140361-24-045002
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20241101
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241101
DATE AS OF CHANGE:		20241101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CareTrust REIT, Inc.
		CENTRAL INDEX KEY:			0001590717
		STANDARD INDUSTRIAL CLASSIFICATION:	REAL ESTATE INVESTMENT TRUSTS [6798]
		ORGANIZATION NAME:           	05 Real Estate & Construction
		IRS NUMBER:				463999490
		STATE OF INCORPORATION:			MD
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36181
		FILM NUMBER:		241419098

	BUSINESS ADDRESS:	
		STREET 1:		905 CALLE AMANECER, SUITE 300
		CITY:			SAN CLEMENTE
		STATE:			CA
		ZIP:			92673
		BUSINESS PHONE:		(949) 542-3140

	MAIL ADDRESS:	
		STREET 1:		905 CALLE AMANECER, SUITE 300
		CITY:			SAN CLEMENTE
		STATE:			CA
		ZIP:			92673
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ny20037824x3_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:ctre="http://caretrustreit.com/20241101" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using Broadridge PROfile 24.9.1.5252
         Copyright 1995 - 2024 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_31b09ac29ee1449bac9eb18b3aed7886" contextRef="c20241101to20241101" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_680836d141464ccc9dca32a67360f7fa" contextRef="c20241101to20241101">0001590717</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ctre-20241101.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20241101to20241101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001590717</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
<div style="line-height: initial;">
  <div>
    <div>
      <div>
        <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

      <div><br/>
      </div>

    </div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

    <div><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_e8fd34e8c96c42969f0306d65901ee92" contextRef="c20241101to20241101">8-K</ix:nonNumeric></div>

    <div><br/>
    </div>

    <div style="text-align: center; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; font-weight: bold;">Pursuant to Section 13 or 15(d)</div>

    <div style="text-align: center; font-weight: bold;">of The Securities Exchange Act of 1934</div>

    <div><br/>
    </div>

    <div style="text-align: center; font-weight: bold;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_0d1d9ec8bf084d3993f2a8f8554ebeec" contextRef="c20241101to20241101" format="ixt:date-monthname-day-year-en">November 1, 2024</ix:nonNumeric></div>

    <div>
      <div><br/>
      </div>

    </div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_24e77630533e492c9aabd50f65d79fe4" contextRef="c20241101to20241101">CareTrust REIT, Inc.</ix:nonNumeric><br/>
    </div>

    <div style="text-align: center; font-weight: bold;">(Exact name of registrant as specified in its charter)</div>

    <div style="text-align: center; font-weight: bold;">&#160; <br/>
    </div>

  </div>

  <div>
    <div>
      <hr style="height: 1px; width: 25%; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>
<div>
    &#160;<br/></div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33.33%; vertical-align: bottom;">
            <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_3ceaf2d26215402095386bf76e0f5f8c" contextRef="c20241101to20241101" format="ixt-sec:stateprovnameen">Maryland</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 33.33%; vertical-align: bottom;">
            <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_677016bf31674dda9e53876e93777ccb" contextRef="c20241101to20241101">001-36181</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 33.34%; vertical-align: bottom;">
            <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_ab7bb32702b640f6b01d9cc304ce8150" contextRef="c20241101to20241101">46-3999490</ix:nonNumeric><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 33.33%; vertical-align: bottom;">
            <div style="text-align: center; font-weight: bold;">(State or other jurisdiction</div>
            <div style="text-align: center; font-weight: bold;">&#160;of incorporation)</div>
          </td>

    <td style="width: 33.33%; vertical-align: bottom;">
            <div style="text-align: center; font-weight: bold;">(Commission</div>
            <div style="text-align: center; font-weight: bold;">&#160;File Number)</div>
          </td>

    <td style="width: 33.34%; vertical-align: bottom;">
            <div style="text-align: center; font-weight: bold;">(IRS Employer</div>
            <div style="text-align: center; font-weight: bold;">&#160;Identification No.)</div>
          </td>

  </tr>


</table>
    <div><br/></div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50%; vertical-align: bottom;">
            <div style="text-align: center; font-weight: bold;"> <ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_ec5e9ccb6e084fcda99b4fc16f172651" contextRef="c20241101to20241101">905 Calle Amanecer, Suite 300</ix:nonNumeric>,</div>
            <div style="text-align: center; font-weight: bold;">&#160;<ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_c7a260357a0b4a85af732675c01a1725" contextRef="c20241101to20241101">San Clemente</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_3fe86d86a05845bea564201fe442865e" contextRef="c20241101to20241101">CA</ix:nonNumeric></div>
          </td>

    <td style="width: 50%; vertical-align: bottom;">
            <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_523407974eeb46b9b689e98a1a3b33e5" contextRef="c20241101to20241101">92673</ix:nonNumeric><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: bottom;">
            <div style="text-align: center; font-weight: bold;">(Address of principal executive offices)</div>
          </td>

    <td style="width: 50%; vertical-align: bottom;">
            <div style="text-align: center; font-weight: bold;">(Zip Code)</div>
          </td>

  </tr>


</table>
    <div style="text-align: center;"><br/>
    </div>

    <div style="text-align: center; font-weight: bold;">Registrant&#8217;s telephone number, including area code (<ix:nonNumeric name="dei:CityAreaCode" id="Fact_f691b477e085408bb6605bf6523e7625" contextRef="c20241101to20241101">949</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_d457f46c1a514b2e843ccee5b400d2bc" contextRef="c20241101to20241101">542-3130</ix:nonNumeric></div>

    <div>
      <div>
        <div>
          <div style="text-align: center; font-weight: bold;">&#160; <br/>
          </div>

        </div>

        <div>
          <div>
            <hr style="height: 1px; width: 25%; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>
<div>
          &#160;</div>
</div>

      </div>

    </div>

    <div>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 4.12%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_b0f11ea7bd49431fa36ff095322712c1" contextRef="c20241101to20241101" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 95.88%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
            <div style="font-family: 'Times New Roman', Times, serif;"> <br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.12%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_4bd75bfe8163423984ab07e8a0d060e4" contextRef="c20241101to20241101" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 95.88%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
            <div style="font-family: 'Times New Roman', Times, serif;"> <br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.12%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_9cec7e15227d4e999228733237a0552b" contextRef="c20241101to20241101" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 95.88%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
            <div style="font-family: 'Times New Roman', Times, serif;"> <br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 4.12%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_3782d26850264e539124a89f758d1be5" contextRef="c20241101to20241101" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 95.88%; vertical-align: top;">
            <div style="font-family: 'Times New Roman', Times, serif;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Sec. 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Sec. 240.12b-2 of this chapter).</div>

    <div><br/>
    </div>

    <div>Emerging growth company&#160; <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_58e3f164eac24571895bdf41f8080fd0" contextRef="c20241101to20241101" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>

    <div><br/>
    </div>

    <div><span style="color: #000000;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
        Section 13(a) of the Exchange Act: </span><span style="font-family: Symbol, serif; color: #000000;">&#160;</span>&#9744;</div>

    <div><br/>
    </div>

    <div>
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <div><span style="font-weight: bold; color: #000000;">Item 8.01</span></div>

    <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 54pt;"><span style="font-weight: bold; color: #000000;">Other Events</span></div>

    <div><br/>
    </div>

    <div style="text-indent: 24.5pt;">On October 30, 2024, CareTrust REIT, Inc. (the &#8220;Company&#8221;) and its operating partnership, CTR Partnership, L.P., entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Wells Fargo Securities, LLC,
      BofA Securities, Inc. and J.P. Morgan Securities LLC, on behalf of themselves and as representatives of the several underwriters named in Schedule I thereto (collectively, the &#8220;Underwriters&#8221;), pursuant to which the Company agreed to sell, and the
      Underwriters agreed to purchase, 13,800,000 shares (the &#8220;Firm Shares&#8221;) of the Company&#8217;s common stock, par value $0.01 per share (the &#8220;Common Stock&#8221;), at an initial price to the public of $32 per share (the &#8220;Purchase Price&#8221;). The Company also granted
      the Underwriters a 30-day option to purchase up to an additional 2,070,000 shares of Common Stock (the &#8220;Option Shares&#8221; and, together with the Firm Shares, the &#8220;Shares&#8221;) at the Purchase Price. The Underwriters exercised their option to purchase the
      Option Shares in full on October 31, 2024.</div>

    <div><br/>
    </div>

    <div style="text-indent: 24.5pt;">The Company issued and delivered the Shares on November 1, 2024.</div>

    <div><br/>
    </div>

    <div style="text-indent: 24.5pt;">The offering of the Shares was made pursuant to the Company&#8217;s automatic shelf registration statement on Form S-3 (File No. 333-269998), filed by the Company with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on
      February 24, 2023, a base prospectus, dated February 24 2023, included as part of the registration statement, and the final prospectus supplement, dated October 30, 2024, filed by the Company with the SEC pursuant to Rule 424(b) under the Securities
      Act of 1933, as amended, on October 31, 2024.</div>

    <div><br/>
    </div>

    <div style="text-indent: 24.5pt;">The Company is filing as Exhibit 5.1 to this Current Report on Form 8-K an opinion of DLA Piper LLP (US) regarding certain matters of Maryland law, including the validity of the Shares issued and sold in the offering.</div>

    <div><br/>
    </div>

    <div style="text-indent: 24.5pt;">The foregoing summary of the Underwriting Agreement is qualified in its entirety by reference to the full text of the Underwriting Agreement, a copy of which is filed as Exhibit 1.1 to this Current Report on Form 8-K
      and is incorporated herein by reference.</div>

    <div><br/>
    </div>

    <div>
<div><span style="font-weight: bold;">Item 9.01</span></div>

      <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 54pt;"><span style="font-weight: bold;">Financial Statements and Exhibits</span></div>

    </div>

    <div><br/>
    </div>

    <div>(d) Exhibits.</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 6%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="color: #000000;">Exhibit No.</div>
            </div>
          </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 92%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="color: #000000;">Description</div>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: top;">
            <div style="color: #000000;"><a href="ny20037824x3_ex1-1.htm">1.1</a></div>
          </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 92%; vertical-align: top;">
            <div><a href="ny20037824x3_ex1-1.htm">Underwriting Agreement, dated October 30, 2024, by and among CareTrust REIT, Inc., CTR Partnership, L.P. and Wells Fargo
                Securities, LLC, BofA Securities, Inc. and J.P. Morgan Securities LLC, on behalf of themselves and as representatives of the several underwriters named in Schedule I thereto.</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: top;">
            <div style="color: #000000;"><a href="ny20037824x3_ex5-1.htm">5.1</a></div>
          </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 92%; vertical-align: top;">
            <div><a href="ny20037824x3_ex5-1.htm">Opinion of DLA Piper LLP (US).</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: top;">
            <div style="color: #000000;"><a href="ny20037824x3_ex5-1.htm">23.1</a></div>
          </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 92%; vertical-align: top;">
            <div><a href="ny20037824x3_ex5-1.htm">Consent of DLA Piper LLP (US) (included in Exhibit 5.1).</a></div>
          </td>

  </tr>

  <tr>

    <td style="width: 6%; vertical-align: top;">
            <div style="color: #000000;">104</div>
          </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 92%; vertical-align: top;">
            <div>Cover Page Interactive Data File (embedded within the inline XBRL document).</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div><br/>
    </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

    </div>

    <div style="text-align: center; font-weight: bold;">SIGNATURES</div>

    <div><br/>
    </div>

    <div style="text-indent: 24.5pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

    <div><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 50.55%; vertical-align: bottom;">&#160;</td>

    <td style="width: 49.45%; vertical-align: bottom;" colspan="2">
            <div style="font-weight: bold;">CARETRUST REIT, INC.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 50.55%; vertical-align: bottom;">&#160;</td>

    <td style="width: 49.45%; vertical-align: bottom;" colspan="2">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50.55%; vertical-align: bottom;">&#160;</td>

    <td style="width: 6.04%; vertical-align: bottom;">
            <div>By:</div>
          </td>

    <td style="width: 43.42%; vertical-align: bottom; border-bottom: #000000 2px solid;">/s/ William M. Wagner<br/>
          </td>

  </tr>

  <tr>

    <td style="width: 50.55%; vertical-align: bottom;">&#160;</td>

    <td style="width: 6.04%; vertical-align: bottom;">
            <div>Name:</div>
          </td>

    <td style="width: 43.42%; vertical-align: bottom; border-top: #000000 2px solid;">
            <div>William M. Wagner</div>
          </td>

  </tr>

  <tr>

    <td style="width: 50.55%; vertical-align: bottom;">&#160;</td>

    <td style="width: 6.04%; vertical-align: bottom;">
            <div>Title:</div>
          </td>

    <td style="width: 43.42%; vertical-align: bottom;">
            <div>Chief Financial Officer and Treasurer</div>
          </td>

  </tr>


</table>
    <div><br/>
    </div>

    <div>Date:</div>

    <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 36pt;">November 1, 2024</div>

    <div><br/>
    </div>

    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

  </div>

</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ny20037824x3_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.9.1.5252
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">





  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade">
    <div>
      <div style="text-align: right; font-weight: bold;">Exhibit 1.1</div>
      <div style="text-align: right; font-weight: bold;"> <br>
         </div>
      <div style="text-align: center; font-weight: bold;">CareTrust REIT, Inc.</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">13,800,000 Shares</div>
      <div>&#160;</div>
      <div style="text-align: center;">Common Stock, par value $0.01 per share</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;"><u>UNDERWRITING AGREEMENT</u></div>
      <div style="text-align: center; font-weight: bold;"><u> <br>
        </u></div>
      <div style="text-align: right;">October 30, 2024</div>
      <div style="text-align: right;"> <br>
         </div>
      <table id="zddccbb12d10543e58eea73da79000804" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="font-weight: normal;">Wells Fargo Securities, LLC</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="font-weight: normal;">BofA Securities, Inc.</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="font-weight: normal;">J.P. Morgan Securities LLC</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="font-weight: normal;">As Representatives of the several Underwriters</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; font-weight: normal;">&#160;</td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="font-weight: normal;">c/o Wells Fargo Securities, LLC</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="font-weight: normal;">500 West 33rd Street, 14th Floor</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="font-weight: normal;">New York, New York 10001</div>
            </td>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div><br>
         </div>
      <div>Ladies and Gentlemen:</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><a name="z_Hlk181115412"></a>CareTrust REIT, Inc., a Maryland corporation (&#8220;<font style="font-weight: bold; font-style: italic;">CareTrust</font>&#8221;), and CTR Partnership, L.P., a Delaware limited
        partnership (the &#8220;<font style="font-weight: bold; font-style: italic;">Operating Partnership</font>&#8221;), confirm their agreement with the several underwriters named in <u>Schedule I</u> hereto (the &#8220;<font style="font-weight: bold; font-style: italic;">Underwriters</font>&#8221;), for whom <a name="z_Hlk181115571"></a>Wells Fargo Securities, LLC, BofA Securities, Inc. and J.P. Morgan Securities LLC are acting as representatives (collectively, in such capacity, the &#8220;<font style="font-weight: bold; font-style: italic;">Representatives</font>&#8221;), with respect to the issuance and sale by CareTrust and the purchase by the Underwriters, acting severally and not jointly, of an aggregate of 13,800,000 shares (the &#8220;<font style="font-weight: bold; font-style: italic;">Firm Shares</font>&#8221;) of <a name="z_Hlk181116078"></a>common stock, par value $0.01 per share, of CareTrust (the &#8220;<font style="font-weight: bold; font-style: italic;">Common Stock</font>&#8221;) from CareTrust. In addition,
        the Underwriters have been granted an option to purchase up to an aggregate of 2,070,000 additional shares of Common Stock (the &#8220;<font style="font-weight: bold; font-style: italic;">Optional Shares</font>&#8221;), if and to the extent that the
        Representatives, as managers of the offering, shall have determined to exercise, on behalf of the Underwriters, the right to purchase such shares of Common Stock granted to the Underwriters, as provided in <u>Section 2</u> hereof. The Firm Shares
        and the Optional Shares are hereinafter collectively referred to as the &#8220;<font style="font-weight: bold; font-style: italic;">Shares</font>.&#8221;</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-indent: 36pt;"><a name="z_Hlk136581485"></a>1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Representations and Warranties of CareTrust and the Operating Partnership</font>.&#160; CareTrust and the Operating Partnership
        each severally represents and warrants to, and agrees with, each of the Underwriters that:</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CareTrust has prepared and filed with the Securities and Exchange Commission (the &#8220;<font style="font-weight: bold; font-style: italic;">Commission</font>&#8221;) an &#8220;automatic shelf registration
        statement&#8221; as defined in Rule 405 (&#8220;<font style="font-weight: bold; font-style: italic;">Rule 405</font>&#8221;) under the Securities Act of 1933, as amended, and the rules and regulations of the Commission promulgated thereunder (collectively, the &#8220;<font style="font-weight: bold; font-style: italic;">Securities Act</font>&#8221;), on Form S-3 (Registration No. 333-269998), including a form of prospectus (the &#8220;<font style="font-weight: bold; font-style: italic;">Base Prospectus</font>&#8221;), to be used in
        connection with the public offering and sale of the Common Stock. Such registration statement, including the financial statements, exhibits and schedules thereto, at the time of effectiveness pursuant to Rule 430A or Rule 430B under the Securities
        Act, including all information and documents incorporated or deemed incorporated by reference therein under the Securities Act or the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (collectively,
        the &#8220;<font style="font-weight: bold; font-style: italic;">Exchange Act</font>&#8221;), is herein called the &#8220;<font style="font-weight: bold; font-style: italic;">Registration Statement</font>.&#8221; The preliminary prospectus supplement dated October 30, 2024
        describing the Shares and the offering thereof, together with the Base Prospectus, is herein called the &#8220;<font style="font-weight: bold; font-style: italic;">Preliminary Prospectus</font>,&#8221; and the Preliminary Prospectus and any other preliminary
        prospectus supplement to the Base Prospectus that describes the Shares and the offering thereof that is used prior to the filing of the Prospectus (as defined below), together with the Base Prospectus, is called a &#8220;preliminary prospectus.&#8221; The
        Preliminary Prospectus, including the Base Prospectus, relating to the Shares that was included in the Registration Statement immediately prior to the Applicable Time (as defined below) is herein called the &#8220;<font style="font-weight: bold; font-style: italic;">Time of Sale Prospectus</font>.&#8221; As used herein, the term &#8220;<font style="font-weight: bold; font-style: italic;">Prospectus</font>&#8221; shall mean the final prospectus supplement to the Base Prospectus that describes the Shares
        and the offering thereof, together with the Base Prospectus, in the form first used by the Underwriters to confirm sales of the Shares or in the form first made available to the Underwriters by CareTrust to meet the requests of purchasers pursuant
        to Rule 173 under the Securities Act. Any &#8220;issuer free writing prospectus&#8221; (as defined in Rule 433 of the Securities Act) is herein called an &#8220;<font style="font-weight: bold; font-style: italic;">Issuer Free Writing Prospectus</font>.&#8221; For purposes
        of this Agreement, all references to the Registration Statement, any preliminary prospectus, the Preliminary Prospectus, the Time of Sale Prospectus, the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to refer to
        and include the copy filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval system (&#8220;<font style="font-weight: bold; font-style: italic;">EDGAR</font>&#8221;). For purposes of this Agreement, the &#8220;<font style="font-weight: bold; font-style: italic;">Applicable Time</font>&#8221; is 6:45 p.m. (Eastern time) on October 30, 2024. As used herein, the terms &#8220;Registration Statement,&#8221; &#8220;preliminary prospectus,&#8221; &#8220;Preliminary Prospectus,&#8221; &#8220;Time of Sale
        Prospectus&#8221; and &#8220;Prospectus&#8221; shall include the documents incorporated and deemed to be incorporated by reference therein.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">All references in this Agreement to financial statements and schedules and other information which is &#8220;contained,&#8221; &#8220;included&#8221; or &#8220;stated&#8221; in, or &#8220;part of&#8221; or other references of like import with
        respect to the Registration Statement, any preliminary prospectus, the Preliminary Prospectus, the Time of Sale Prospectus or the Prospectus shall be deemed to mean and include all such financial statements and schedules and other information that
        is or is deemed to be incorporated by reference in the Registration Statement, any preliminary prospectus, the Preliminary Prospectus, the Time of Sale Prospectus or the Prospectus, as the case may be; and all references in this Agreement to
        amendments or supplements to the Registration Statement, any preliminary prospectus, the Preliminary Prospectus, the Time of Sale Prospectus or the Prospectus shall be deemed to mean and include the filing of any document under the Exchange Act
        that is incorporated by reference in the Registration Statement, any preliminary prospectus, the Preliminary Prospectus, the Time of Sale Prospectus or the Prospectus, as the case may be.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">2</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i) At the time of filing the Registration Statement, (ii) at the earliest time that Caretrust or another offering participant made a <font style="font-style: italic;">bona fide</font>
        offer (within the meaning of Rule 164 under the Securities Act) of the Shares and (iii) at the date hereof, CareTrust was not and is not an &#8220;ineligible issuer&#8221; in connection with the offering of the Shares pursuant to Rules 164, 405 and 433 under
        the Securities Act. No order preventing or suspending the use of any preliminary prospectus, the Time of Sale Prospectus or any Issuer Free Writing Prospectus has been issued by the Commission. Each preliminary prospectus, the Time of Sale
        Prospectus and the Prospectus, at the time of filing thereof, complied, and any further amendments or supplements thereto will comply, in all material respects, with the Securities Act, and did not contain an untrue statement of a material fact or
        omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The representation and warranty set forth in the immediately preceding sentence does
        not apply to statements or omissions made in reliance upon and in conformity with written information relating to any Underwriter furnished to CareTrust in writing by the Representatives expressly for inclusion therein, which information consists
        solely of the information set forth in <u>Section 7(b)</u> hereof.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Time of Sale Prospectus, as supplemented by those Issuer Free Writing Prospectuses and other materials and information listed in <u>Schedule II</u> hereto, taken together
        (collectively, the &#8220;<font style="font-weight: bold; font-style: italic;">Disclosure Package</font>&#8221;) as of the Applicable Time, complied, in all material respects, with the Securities Act, and did not include any untrue statement of a material fact
        or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. Each Issuer Free Writing Prospectus listed on <u>Schedule II</u> or <u>Schedule
          III</u> hereto does not conflict with the information contained in the Registration Statement, the Time of Sale Prospectus or the Prospectus, and each such Issuer Free Writing Prospectus, as supplemented by and taken together with the Disclosure
        Package as of the Applicable Time, did not include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
        misleading. The representations and warranties set forth in the two immediately preceding sentences do not apply to statements or omissions made in reliance upon and in conformity with written information relating to any Underwriter furnished to
        CareTrust in writing by the Representatives expressly for inclusion therein, which information consists solely of the information set forth in <u>Section 7(b)</u> hereof.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Registration Statement and any post-effective amendment thereto have become effective under the Securities Act. CareTrust has responded to all requests, if any, of the Commission for
        additional or supplemental information. No stop order suspending the effectiveness of the Registration Statement is in effect and no proceedings for such purpose or pursuant to Section 8A of the Securities Act have been instituted or are pending
        or, to CareTrust&#8217;s best knowledge, are contemplated or threatened by the Commission.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Registration Statement complies, and the Prospectus and any further amendments or supplements thereto will comply, in each case in all material respects, with the Securities Act. The
        Registration Statement, and any post-effective amendment thereto, does not and will not contain, as of the applicable effective date, any untrue statement of a material fact or omit to state a material fact required to be stated therein or
        necessary to make the statements therein not misleading. The Prospectus, and any supplements thereto, as of its date or the date of such supplement and on each Delivery Date (as defined below), does not and will not contain any untrue statement of
        a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The representations and warranties set forth in the two immediately
        preceding sentences do not apply to statements or omissions made in reliance upon and in conformity with written information furnished to CareTrust by an Underwriter expressly for inclusion therein, which information consists solely of the
        information set forth in <u>Section 7(b)</u> hereof. There are no contracts or other documents required to be described in the Time of Sale Prospectus or the Prospectus or filed as exhibits to the Registration Statement that have not been
        described or filed as required.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">3</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Time of Sale Prospectus was, and the Prospectus delivered to the Underwriters for use in connection with this offering will be, identical to the versions of the Time of Sale Prospectus
        and Prospectus created to be transmitted to the Commission for filing via EDGAR, except to the extent permitted by Regulation S-T.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At the time the Registration Statement originally became effective, CareTrust was permitted to use Form S-3 under the Securities Act.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i) At the time of filing the Registration Statement, (ii) at the time of the most recent amendment thereto for the purposes of complying with Section 10(a)(3) of the Securities Act
        (whether such amendment was by post-effective amendment, incorporated report filed pursuant to Section 13 or 15(d) of the Exchange Act or form of prospectus), (iii) at the time CareTrust made any offer relating to the Shares in reliance on the
        exemption of Rule 163 of the Securities Act and (iv) at the date hereof, CareTrust was and is a &#8220;well-known seasoned issuer&#8221; as defined in Rule 405. The Shares, since their registration on the Registration Statement, have been and remain eligible
        for registration by CareTrust on a Rule 405 &#8220;automatic shelf registration statement.&#8221; CareTrust has not received from the Commission any notice pursuant to Rule 401(g)(2) of the Securities Act objecting to the use of the Registration Statement.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The documents incorporated by reference or deemed to be incorporated by reference in the Disclosure Package and the Prospectus, when they were filed with the Commission, conformed in all
        material respects to the requirements of the Exchange Act, and did not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which
        they were made, not misleading; and any further documents so filed and incorporated by reference or deemed to be incorporated by reference in the Disclosure Package or the Prospectus or any supplement thereto, when such documents are filed with the
        Commission, will conform in all material respects to the requirements of the Exchange Act and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light
        of the circumstances under which they were made, not misleading.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">4</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as otherwise disclosed in the Registration Statement, the Disclosure Package and the Prospectus, since the respective dates as of which information is given in the Registration
        Statement, the Disclosure Package and the Prospectus (in each case exclusive of any amendments or supplements thereto subsequent to the date of this Agreement), (i) there has been no material adverse change or any development that could reasonably
        be expected to result in a material adverse change, in the condition (financial or other), results of operations, business, properties, management or prospects of CareTrust, the Operating Partnership or the direct and indirect subsidiaries (as
        defined in Rule 1-02(x) of Regulation S-X) of CareTrust and/or the Operating Partnership (the &#8220;<font style="font-weight: bold; font-style: italic;">Subsidiaries</font>&#8221;), taken as a whole (in any such case, a &#8220;<font style="font-weight: bold; font-style: italic;">Material Adverse Effect</font>&#8221;); (ii) none of CareTrust, the Operating Partnership or any of the Subsidiaries has incurred any liability or obligation, direct or contingent, or entered into any transaction or agreement that,
        individually or in the aggregate, is material with respect to CareTrust, the Operating Partnership and the Subsidiaries taken as a whole, and none of CareTrust, the Operating Partnership and the Subsidiaries has sustained any loss or interference
        with its business or operations from fire, explosion, flood, earthquake or other natural disaster or calamity, whether or not covered by insurance, or from any labor dispute or disturbance or court or governmental action, order or decree which
        could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect; and (iii) there has been no distribution of any kind declared, paid or made by the Operating Partnership on any partnership interest, other than
        distributions paid to CareTrust or CareTrust GP, LLC.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each of CareTrust, the Operating Partnership and the Subsidiaries has been duly incorporated or organized, as applicable, and is validly existing as a corporation, limited partnership or
        limited liability company, as the case may be, in good standing under the laws of the state of its jurisdiction of incorporation or organization, as applicable, and has the power and authority to own, lease and operate its properties and to conduct
        its business as described in the Disclosure Package and the Prospectus, except where the failure to be in good standing or have such power and authority would not, individually or in the aggregate, reasonably be expected to result in a Material
        Adverse Effect. Each of CareTrust, the Operating Partnership and the Subsidiaries is duly qualified as a foreign corporation, limited partnership or limited liability company, as the case may be, to transact business and is in good standing in each
        jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to so qualify or to be in good standing would not, individually or in the
        aggregate, reasonably be expected to result in a Material Adverse Effect. CareTrust owns 100% of CareTrust GP, LLC, which is the sole general partner of the Operating Partnership.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All of the issued and outstanding shares of each of CareTrust and the Subsidiaries that is a corporation, all of the issued and outstanding partnership interests of each of the Operating
        Partnership and the Subsidiaries that is a limited partnership and all of the issued and outstanding limited liability company interests, membership interests or other similar interests of each of the Subsidiaries that is a limited liability
        company have been duly authorized and validly issued, are (except in the case of general partnership interests and limited liability company interests) fully paid and non-assessable and were issued in compliance with all applicable state and
        federal securities and &#8220;Blue Sky&#8221; laws, and are owned by CareTrust, directly or through subsidiaries, free and clear of any lien, security interest, mortgage, pledge, encumbrance or claim (each, a &#8220;<font style="font-weight: bold; font-style: italic;">Lien</font>&#8221;), except as otherwise disclosed in the Disclosure Package and the Prospectus. None of the issued and outstanding shares of capital stock of any of CareTrust and the Subsidiaries that is a corporation, none of the issued and
        outstanding partnership interests of any of the Operating Partnership and the Subsidiaries that is a limited or general partnership, and none of the issued and outstanding limited liability company interests, membership interests or other similar
        interests of any Subsidiary that is a limited liability company was issued in violation of any preemptive rights, rights of first refusal or other similar rights of any security holder of such entity or any other person. Except with respect to
        preferred equity investments in joint ventures as disclosed in the Disclosure Package and the Prospectus, each of CareTrust and the Operating Partnership does not own or control, directly or indirectly, any corporation, association or other entity
        other than the Subsidiaries; the Operating Partnership is a Subsidiary of CareTrust.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">5</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; This Agreement has been duly authorized, executed and delivered by each of CareTrust and the Operating Partnership. Each of CareTrust and the Operating Partnership has full right, power and
        authority to execute, deliver and perform its obligations under this Agreement.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CareTrust has an authorized capitalization as set forth in the Disclosure Package and the Prospectus. The shares of issued and outstanding capital stock of CareTrust have been duly
        authorized and validly issued and are fully paid and non-assessable and were issued in compliance with all applicable state and federal securities and &#8220;Blue Sky&#8221; laws.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(o)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Common Stock conforms in all material respects to the statements relating thereto contained in the Registration Statement, the Disclosure Package and the Prospectus; the Shares have
        been duly authorized and, when issued and delivered in accordance with the terms of this Agreement, will be validly issued, fully paid and nonassessable, and conform to the description thereof contained in the Disclosure Package and the Prospectus.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(p)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other than as described in the Disclosure Package and the Prospectus, there are no contracts, agreements or understandings between CareTrust and any person granting such person the right
        to require CareTrust to file a registration statement under the Securities Act with respect to any shares of Common Stock or any other securities of CareTrust owned or to be owned by such person or to require CareTrust to include such Common Stock
        or other securities in the Registration Statement. To the extent any person has such registration or offer similar rights, such rights have been waived with respect to the registration of securities in connection with the Registration Statement.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(q)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No consent, approval, authorization, or order of, or filing or registration with, any governmental agency or body or any court is required for the consummation of the transactions
        contemplated by this Agreement, except (i) such as have been made or obtained under the Securities Act, or (ii) the consents, approvals, authorizations, registrations or qualifications as may be required by state securities or &#8220;Blue Sky&#8221; laws or by
        the Financial Industry Regulatory Authority (&#8220;<font style="font-weight: bold; font-style: italic;">FINRA</font>&#8221;).</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(r)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;None of CareTrust, the Operating Partnership or the Subsidiaries is (i) in violation of its (a) in the case of a corporation, charter and by-laws; (b) in the case of a limited or general
        partnership, partnership certificate, certificate of formation or similar organizational document and partnership agreement; (c) in the case of a limited liability company, articles of organization, certificate of formation or similar
        organizational documents and operating agreement, limited liability company agreement, membership agreement or other similar agreement; (d) in the case of a trust, certificate of trust, certificate of formation or similar organizational document
        and trust agreement or other similar agreement; and (e) in the case of any other entity, the organizational and governing documents of such entity, (ii) in violation of any applicable law, statute, rule, regulation, judgment, order, writ or decree
        of any government, government instrumentality or court, domestic or foreign, having jurisdiction over CareTrust, the Operating Partnership or the Subsidiaries or any of their respective assets, properties or operations or (iii) in breach or default
        (or with or without the giving of notice or the passage of time or both, would be in breach or default) in the performance or observance of any obligation, agreement, covenant or condition contained in any contracts, indentures, mortgages, deeds of
        trust, loan or credit agreements, bonds, notes, debentures, evidences of indebtedness, swap agreements, leases or other instruments or agreements to which it is a party or by which it is bound or to which any of its property or assets are subject
        (collectively, &#8220;<font style="font-weight: bold; font-style: italic;">Company Documents</font>&#8221;), except, in the cases of clauses (ii) or (iii) for such violations, breaches or defaults that would not, individually or in the aggregate, reasonably be
        expected to result in a Material Adverse Effect.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">6</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(s)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The execution, delivery and performance by CareTrust and the Operating Partnership of this Agreement and the consummation by CareTrust, the Operating Partnership and the Subsidiaries of
        the issuance and sale of the Shares and the use of the proceeds from the sale of the Shares as described in the Disclosure Package and the Prospectus under the caption &#8220;Use of Proceeds&#8221; and compliance by CareTrust and the Operating Partnership with
        their respective obligations under this Agreement, (i) do not and will not, whether with or without the giving of notice or passage of time or both, conflict with or constitute a breach of, or default, event or condition which gives any person the
        right, either immediately or with notice or passage of time or both, to terminate or limit (in whole or in part) any Company Documents or any rights of CareTrust, the Operating Partnership or any Subsidiary thereunder including, without limitation,
        upon the occurrence of a change of control of any of CareTrust, the Operating Partnership or any Subsidiary or other similar events (each, a &#8220;<font style="font-weight: bold; font-style: italic;">Termination Event</font>&#8221;) or event or condition
        which, either immediately or with notice or passage of time or both, (a) gives the holder of any bond, note, debenture or other evidence of indebtedness (or any person acting on such holder&#8217;s behalf) the right to require the repurchase, redemption
        or repayment of all or a portion of such indebtedness by CareTrust, the Operating Partnership or any Subsidiary, or (b) gives any counterparty (or any person acting on such counterparty&#8217;s behalf) under any swap agreement, hedging agreement or
        similar agreement or instrument to which CareTrust, the Operating Partnership or any Subsidiary is a party the right to liquidate or accelerate the payment obligations or designate an early termination date under such agreement or instrument, as
        the case may be (each, a &#8220;<font style="font-weight: bold; font-style: italic;">Repayment Event</font>&#8221;) under, or result in the creation or imposition of any Lien upon any property or assets of CareTrust, the Operating Partnership or any Subsidiary
        pursuant to, any Company Documents, except for any such conflict, breach, default, Termination Event, Repayment Event or Lien that would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect, and (ii)
        will not result in any violation of (a) the provisions of the organizational documents of CareTrust, the Operating Partnership or any Subsidiary or (b) (assuming compliance with any applicable securities or &#8220;Blue Sky&#8221; laws of the jurisdictions in
        which the Shares are offered by the Underwriters and assuming that the Underwriters comply with the agreements contained herein) law, statute, rule, regulation, judgment, order, writ or decree of any government, government instrumentality or court,
        domestic or foreign, having jurisdiction over CareTrust, the Operating Partnership or any Subsidiary or any of their respective assets, properties or operations.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">7</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(t)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as otherwise disclosed in the Disclosure Package and the Prospectus, (i) CareTrust, the Operating Partnership and the Subsidiaries have good and marketable title (in fee simple) to
        all assets described in the Disclosure Package and the Prospectus as being owned by them, and none of CareTrust, the Operating Partnership or any Subsidiary has received notice of any claim that has been or may be asserted by anyone adverse to the
        rights of CareTrust, the Operating Partnership or any Subsidiary with respect to such assets or affecting or questioning the rights of any of CareTrust, the Operating Partnership or any Subsidiary to the continued ownership, possession or occupancy
        of such assets, except for such claims that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; (ii) all Liens or restrictions on or affecting the assets CareTrust, the Operating Partnership or any
        Subsidiary that are required to be disclosed in the Disclosure Package or the Prospectus are disclosed therein, and all such Liens or restrictions which are not disclosed in the Disclosure Package and the Prospectus could not reasonably be
        expected, individually or in the aggregate, to have a Material Adverse Effect; (iii) no person or entity has an option or right of first refusal or any other right to purchase any of the assets leased to or owned by CareTrust, the Operating
        Partnership or any Subsidiary, except where any such option or right would not, individually or in the aggregate, have a Material Adverse Effect; (iv) each of the assets leased to or owned by CareTrust, the Operating Partnership or any Subsidiary
        has access to public rights of way, either directly or through insured easements, except where the failure to have such access would not, individually or in the aggregate, have a Material Adverse Effect; (v) each of the assets controlled by
        CareTrust, the Operating Partnership or any Subsidiary is served by all public utilities necessary for the current operations on such property sufficient for such operations, except where the failure to have such public utilities would not,
        individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; (vi) the assets leased to or owned by CareTrust, the Operating Partnership or any Subsidiary comply, in all material respects, with all applicable codes and
        zoning and subdivision laws and regulations or the use thereof is permitted as a legal non-conforming use; (vii) all of the leases under which CareTrust, the Operating Partnership or any Subsidiary leases (as lessee) any real property or
        improvements or any equipment relating to such real property or improvements are in full force and effect, except where the failure to be in full force and effect would not, individually or in the aggregate, reasonably be expected to have a
        Material Adverse Effect, and none of CareTrust, the Operating Partnership or any Subsidiary is in default in the payment of any amounts due under any such leases or otherwise in default thereunder and none of CareTrust, the Operating Partnership or
        any Subsidiary knows of any event that, with the passage of time or the giving of notice or both, would constitute a default under any such lease, except such defaults that would not, individually or in the aggregate, reasonably be expected to have
        a Material Adverse Effect; (viii) there is no pending or, to the knowledge of CareTrust, the Operating Partnership or any Subsidiary, threatened condemnation, zoning change, or other proceeding or action that could in any manner affect the size of,
        use of, improvements on, construction on or access to any asset leased to or owned by CareTrust, the Operating Partnership or any Subsidiary, except such proceedings or actions that, either individually or in the aggregate, would not reasonably be
        expected to have a Material Adverse Effect; and (ix) all of the leases under which CareTrust, the Operating Partnership or any Subsidiary leases (as lessor) any real property or improvements (whether directly or indirectly through partnerships,
        joint ventures or otherwise) are in full force and effect, except where the failure to be in full force and effect would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, and none of CareTrust, the
        Operating Partnership or any Subsidiary nor any lessee of any of the real property or improvements of CareTrust, the Operating Partnership or any Subsidiary is in default in the payment of any amounts due under any such leases or otherwise in
        default thereunder, and none of CareTrust, the Operating Partnership or any Subsidiary knows of an event which, with the passage of time or the giving of notice or both, would constitute such a default under any of such leases, except such defaults
        as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">8</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(u)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CareTrust, the Operating Partnership and the Subsidiaries possess such permits, licenses, approvals, accreditations, certifications, registrations, certificates, consents and other
        authorizations (collectively, &#8220;<font style="font-weight: bold; font-style: italic;">Governmental Licenses</font>&#8221;) issued by the appropriate federal, state, local or foreign regulatory agencies or bodies to the extent required to conduct the
        business to be operated by them as described in the Disclosure Package and the Prospectus, except where the failure to possess such Governmental Licenses would not, individually or in the aggregate, reasonably be expected to result in a Material
        Adverse Effect. CareTrust, the Operating Partnership and the Subsidiaries are in compliance with the terms and conditions of all such Governmental Licenses, except where the failure so to comply would not, individually or in the aggregate, result
        in a Material Adverse Effect. None of CareTrust, the Operating Partnership or any Subsidiary has received any written notice of proceedings relating to the revocation or modification of any such Governmental Licenses, except where such revocation
        or modification would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The statements made in or incorporated by reference into the Disclosure Package and the Prospectus, insofar as they purport to constitute summaries of the terms of statutes, rules or
        regulations, legal or governmental proceedings or contracts and other documents, constitute accurate summaries of the terms of such statutes, rules and regulations, legal and governmental proceedings and contracts and other documents in all
        material respects.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(w)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; There is no action, suit, proceeding, inquiry or investigation before or brought by any court or governmental agency or body, domestic or foreign, now pending, or, to the knowledge of
        CareTrust, the Operating Partnership or any of the Subsidiaries, threatened, against or affecting CareTrust, the Operating Partnership or any of the Subsidiaries (other than as disclosed in the Disclosure Package or the Prospectus) which could
        reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(x)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No labor dispute with the employees of any of CareTrust, the Operating Partnership or any Subsidiary exists or, to the knowledge of CareTrust, the Operating Partnership or any Subsidiary,
        is imminent, in each case, which could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect or to materially and adversely affect the consummation of the transactions contemplated in this Agreement or the
        performance by any of CareTrust or the Operating Partnership of its obligations under this Agreement.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">9</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(y)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;None of the following events has occurred or exists: (i) a failure to fulfill the obligations, if any, under the minimum funding standards of Section 302 of the Employee Retirement Income
        Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &#8220;<font style="font-weight: bold; font-style: italic;">ERISA</font>&#8221;) with respect to a Plan determined without regard to any waiver of
        such obligations or extension of any amortization period; (ii) an audit or investigation by the Internal Revenue Service, the U.S. Department of Labor, the Pension Benefit Guaranty Corporation or any other federal, state or foreign governmental or
        regulatory agency with respect to the employment, compensation or benefits of employees of CareTrust, the Operating Partnership or any Subsidiary that could reasonably be expected, individually or in the aggregate, to result in a Material Adverse
        Effect; or (iii) any breach or termination of any contractual obligation, or any violation of law or applicable qualification standards, with respect to the employment, compensation or benefits of employees of CareTrust, the Operating Partnership
        or any Subsidiary or with respect to a Plan that could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. None of the following events has occurred or is reasonably likely to occur: (i) a material
        increase in the aggregate amount of contributions required to be made to all Plans in the current fiscal year of CareTrust, the Operating Partnership and any Subsidiary compared to the amount of such contributions made in CareTrust&#8217;s most recently
        completed fiscal year; (ii) a material increase in the &#8220;accumulated post-retirement benefit obligations&#8221; (within the meaning of Statement of Financial Accounting Standards 106) of CareTrust, the Operating Partnership and the Subsidiaries in the
        current fiscal year of CareTrust, the Operating Partnership and any Subsidiary compared to the amount of such obligations in CareTrust&#8217;s most recently completed fiscal year; (iii) any event or condition giving rise to a liability under Title IV of
        ERISA with respect to a Plan that could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect; or (iv) the filing of a claim by one or more employees or former employees of CareTrust, the Operating
        Partnership or any Subsidiary related to its or their employment that could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. For purposes of this paragraph, the term &#8220;<font style="font-weight: bold; font-style: italic;">Plan</font>&#8221; means a plan (within the meaning of Section 3(3) of ERISA) with respect to which CareTrust, the Operating Partnership or any Subsidiary may have any liability.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(z)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i) CareTrust, the Operating Partnership and the Subsidiaries own and possess or have valid and enforceable licenses to use, all patents, patent rights, patent applications, licenses,
        copyrights, inventions, know how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks, trade names, service names, software, internet addresses,
        domain names and other intellectual property (collectively, &#8220;<font style="font-weight: bold; font-style: italic;">Intellectual Property</font>&#8221;) that are described in the Disclosure Package or the Prospectus or that are necessary for the conduct of
        their respective businesses as described in the Disclosure Package and the Prospectus; (ii) none of CareTrust, the Operating Partnership or any Subsidiary has received any notice or is otherwise aware of any infringement of or conflict with rights
        of others with respect to any Intellectual Property or of any facts or circumstances which would render any Intellectual Property invalid or inadequate to protect the interests of CareTrust, the Operating Partnership or any Subsidiary therein;
        (iii) there are no third parties who have or, to the knowledge of CareTrust, the Operating Partnership or any Subsidiary, will be able to establish rights to any Intellectual Property of CareTrust, the Operating Partnership or any Subsidiary and
        (iv) there is no pending or, to the knowledge of CareTrust, the Operating Partnership or any Subsidiary, threatened action, suit, proceeding or claim by others challenging CareTrust&#8217;s, the Operating Partnership&#8217;s or any Subsidiary&#8217;s rights in or to
        any such Intellectual Property, except in the case of each of clauses (i)-(iv) as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">10</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(aa)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as otherwise disclosed in the Disclosure Package and the Prospectus: (i) to the best knowledge of CareTrust, the assets controlled by CareTrust, the Operating Partnership and the
        Subsidiaries, including, without limitation, the Environment (as defined below) associated with such assets, is free of any Contaminant (as defined below), except such Contaminants which, individually or in the aggregate, would not reasonably be
        expected to have a Material Adverse Effect; (ii) none of CareTrust, the Operating Partnership or any Subsidiary has caused any Release (as defined below) of any Contaminant into the Environment that, individually or in the aggregate, could
        reasonably be expected to have a Material Adverse Effect or could result in any violation of any Environmental Laws (as defined below) or constitute a health or safety (as such matters relate to Contaminants) or environmental hazard to any person
        or property except for such violations or hazards that could not reasonably be expected to have a Material Adverse Effect; (iii) none of CareTrust, the Operating Partnership or any Subsidiary is aware of any written notice from any governmental
        body or other person claiming any violation of or liability under any Environmental Laws or requiring or calling attention to the need for any work, repairs, construction, alterations, removal or remedial action or installation on or in connection
        with such real property or improvements relating to the presence of asbestos containing materials or other Contaminants on, at, under or migrating to or from such properties, except for such violations, work, repairs, construction, alterations,
        removal or remedial actions or installations as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; (iv) any such work, repairs, construction, alterations, removal or remedial action or
        installation, if required, would not result in the incurrence of liabilities, which, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect; (v) none of the Subsidiaries has caused or suffered to exist or
        occur any condition on any of the properties or improvements of CareTrust, the Operating Partnership or any Subsidiary that could give rise to the imposition of any Lien under any Environmental Laws, except such Liens which, individually or in the
        aggregate, would not reasonably be expected to have a Material Adverse Effect; (vi) no real property or improvements owned or leased by any Subsidiary is being used, or to the knowledge of CareTrust, the Operating Partnership or any Subsidiary, has
        been used, for manufacturing or for any other operations that involve or involved the use, handling, transportation, storage, treatment or Release of any Contaminant, where such operations require or required permits or are or were otherwise
        regulated pursuant to the Environmental Laws and where such permits have not been or were not obtained or such regulations or such permits are not being or were not complied with, except in all instances where any failure to obtain a permit or
        comply with any regulation or permit could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect; (vii) none of CareTrust, the Operating Partnership or any Subsidiary is aware of any facts or issues
        relating to compliance with Environmental Law that would reasonably be expected to have a Material Adverse Effect on their capital expenditures, earnings or competitive position; and (viii) there are no proceedings that are pending against
        CareTrust, the Operating Partnership or any Subsidiary to which a governmental entity is also a party, other than such proceedings as to which CareTrust reasonably believes that no monetary sanctions of $300,000 (or, if the CareTrust has so elected
        pursuant to Item 103(c)(3)(iii) of Regulation S-K, the lesser of $1,000,000 or one percent of the current assets of CareTrust and its Subsidiaries on a consolidated basis) or more will be imposed. &#8220;<font style="font-weight: bold; font-style: italic;">Contaminant</font>&#8221; means any pollutant, contaminant, hazardous substance, toxic substance, hazardous waste, special waste, biohazardous waste, petroleum or petroleum derived substance or waste, asbestos or asbestos containing materials,
        PCBs, lead, pesticides, per- or polyfluoroalkyl substances, toxic mold, radon or radioactive materials or any constituent of any such substance or waste, including any substance, material or waste identified or regulated under any Environmental
        Law. &#8220;<font style="font-weight: bold; font-style: italic;">Environmental Laws</font>&#8221; means the Comprehensive Environmental Response, Compensation and Liability Act, 42 U.S.C. &#167; 9601 et seq., the Resource Conservation and Recovery Act, 42 U.S.C. &#167;
        6901 et seq., the Clean Air Act, 42 U.S.C. &#167; 7401 et seq., the Clean Water Act, 33 U.S.C. &#167; 1251 et seq., the Toxic Substances Control Act, 15 U.S.C. &#167; 2601 et seq., the Occupational Safety and Health Act, 29 U.S.C. &#167; 651 et seq., and all other
        federal, state and local laws, common law, ordinances, regulations, rules, orders, decisions, permits, and the like, which are directed at the protection of human health (as it relates to Contaminants) or the Environment. &#8220;<font style="font-weight: bold; font-style: italic;">Environment</font>&#8221; means any surface water, drinking water, ground water, land surface, subsurface strata, river sediment, buildings, structures, and ambient, workplace and indoor air. &#8220;<font style="font-weight: bold; font-style: italic;">Release</font>&#8221; means any spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, migrating, dumping, emanating or disposing of any Contaminant into the Environment, including,
        without limitation, the abandonment or discard of barrels, containers, tanks or other receptacles containing or previously containing any Contaminant or any release, emission or discharge as those terms are defined or used in any Environmental Law.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">11</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(bb)&#160;&#160;&#160;&#160;&#160;&#160;&#160; None of CareTrust, the Operating Partnership and the Subsidiaries participate in, submit claims to, or receive payment from the Medicare program, the respective Medicaid program in the
        state or states in which such entity operates, or any other third party payor program.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(cc)&#160;&#160;&#160;&#160;&#160;&#160;&#160; CareTrust, the Operating Partnership and the Subsidiaries, to the extent applicable in connection with their business, are in compliance with the Health Insurance Portability and
        Accountability Act of 1996 (as amended, and including 45 C.F.R. Part 160 and Part 164 and any other regulations promulgated thereunder) (collectively, &#8220;<font style="font-weight: bold; font-style: italic;">HIPAA</font>&#8221;) and with applicable
        provisions of Federal or state laws governing Medicare or any state Medicaid programs and any regulations promulgated pursuant to such laws, including, without limitation, Sections 1320a-7, 1320a-7a, 1320a-7b and 1395nn of Title 42 of the United
        States Code, the False Claims Act, 31 U.S.C. &#167; 3729 et seq., all criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. &#167; 286 and 18 U.S.C. &#167; 287, and the health care fraud criminal provisions under HIPAA (18
        U.S.C. &#167; 1347), Medicare (Title XVIII of the Social Security Act), Medicaid (Title XIX of the Social Security Act) and related state or local regulations promulgated under such laws (collectively, &#8220;<font style="font-weight: bold; font-style: italic;">Health Care Laws</font>&#8221;), corporate integrity and settlement agreements or any rules of professional conduct, except for such provisions the violation of which would not, individually or in the aggregate, reasonably be expected to have
        a Material Adverse Effect.&#160; CareTrust, the Operating Partnership and the Subsidiaries have not engaged in activities that are, as applicable, cause for false claims liability or civil penalties under the Health Care Laws.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(dd)&#160;&#160;&#160;&#160;&#160;&#160;&#160; [Reserved]</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(ee)&#160;&#160;&#160;&#160;&#160;&#160;&#160; [Reserved]</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(ff)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[Reserved]</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">12</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(gg)&#160;&#160;&#160;&#160;&#160;&#160;&#160; CareTrust, the Operating Partnership and the Subsidiaries have filed all foreign, federal, state, local and franchise tax returns that are required to be filed or have obtained extensions
        thereof, except where the failure so to file would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect, and have paid all taxes (including, without limitation, any estimated taxes) required to be
        paid and any other assessment, fine or penalty, to the extent that any of the foregoing is due and payable, except for any such tax, assessment, fine or penalty that is currently being contested in good faith by appropriate actions and except for
        such taxes, assessments, fines or penalties the nonpayment of which would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(hh)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Commencing with CareTrust&#8217;s taxable year ending December 31, 2014, CareTrust has been and is organized and operated in conformity with the requirements for qualification and taxation as a
        &#8220;real estate investment trust&#8221; (a &#8220;<font style="font-weight: bold; font-style: italic;">REIT</font>&#8221;) under Sections 856 through 860 of the Internal Revenue Code of 1986 (the &#8220;<font style="font-weight: bold; font-style: italic;">Code</font>&#8221;); and
        CareTrust&#8217;s proposed method of operation as described in the Disclosure Package and Prospectus will enable CareTrust to meet the requirements for qualification and taxation as a REIT under the Code.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;None of CareTrust, the Operating Partnership or any Subsidiary is party to any tax sharing or other revenue sharing agreement, other than the Tax Matters Agreement, dated as of May 30,
        2014, by and between The Ensign Group, Inc. and CareTrust.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(jj)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, CareTrust, the Operating Partnership and the Subsidiaries have title
        insurance on all real property and improvements owned by or leased to any of them under a ground lease, as the case may be, in each case in an amount at least equal to the original cost of acquisition, and CareTrust, the Operating Partnership or a
        Subsidiary, as applicable, is entitled to all benefits of the insured thereunder. Each such property is insured by extended coverage hazard and casualty insurance in amounts and on such terms as are customarily carried by owners and, if applicable,
        lessors and lessees, of similar properties (in the markets in which the properties of CareTrust, the Operating Partnership and the Subsidiaries are located). CareTrust, the Operating Partner and the Subsidiaries carry comprehensive general
        liability insurance and such other insurance as is customarily carried by owners and, if applicable, lessors of properties similar to those leased to or owned by CareTrust, the Operating Partnership and the Subsidiaries, and require the lessee
        under each lease of any such property to a third party to carry comprehensive general liability insurance and such other insurance as is customarily carried by lessees, in each case in amounts and on such terms as are customarily carried by owners,
        lessors and lessees, as applicable, of similar properties (in the markets in which the properties of CareTrust, the Operating Partnership and the Subsidiaries are located). CareTrust, the Operating Partnership or Subsidiary, as applicable, is named
        as an additional insured on all policies required to be carried by third-party lessees under the leases for such properties.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(kk)&#160;&#160;&#160;&#160;&#160;&#160;&#160; None of the Operating Partnership or any Subsidiary is a party to or otherwise bound by any instrument or agreement that limits or prohibits or could limit or prohibit, directly or
        indirectly, any Subsidiary from paying any dividends or making any other distributions on its capital stock, limited or general partnership interests, limited liability company interests, or other equity interests, as the case may be, or from
        repaying any loans or advances from, or (except for instruments or agreements that by their express terms prohibit the transfer or assignment thereof or of any rights thereunder) transferring any of its properties or assets to, the Operating
        Partnership or any other Subsidiary, in each case except as described in the Disclosure Package and the Prospectus.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">13</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(ll)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The consolidated financial statements of CareTrust, together with the related schedule and notes thereto, included or incorporated by reference in the Registration Statement, the
        Disclosure Package and the Prospectus present fairly in all material respects the financial position of CareTrust at the dates indicated and the results of operations, changes in invested equity and cash flows of CareTrust for the periods
        specified. Such financial statements have been prepared in conformity with generally accepted accounting principles or &#8220;<font style="font-weight: bold; font-style: italic;">GAAP</font>&#8221; (as defined in Item 10 of Regulation S-K), applied on a
        consistent basis throughout the periods involved and comply with all applicable accounting requirements under the Securities Act, or the Exchange Act, as applicable, and no other financial statements or supporting schedules are required to be
        included in the Registration Statement, the Disclosure Package or the Prospectus pursuant to Rule 3-14 of Regulation S-X or otherwise. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the
        Registration Statement fairly presents the required information called for in all material respects and has been prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(mm)&#160;&#160;&#160;&#160;&#160; Except as otherwise disclosed in the Registration Statement, the Disclosure Package and the Prospectus, subsequent to the respective dates as of which information is given in the Prospectus,
        neither CareTrust, the Operating Partnership nor any of the Subsidiaries has sustained any loss or interference with its business material to CareTrust, the Operating Partnership and the Subsidiaries considered as a whole, and there has not been
        any (i) material change in the capitalization of CareTrust, the Operating Partnership or the Subsidiaries, (ii) material increase in the aggregate in the consolidated short-term or long-term debt of CareTrust, (iii) transaction that is material to
        CareTrust, the Operating Partnership or any of the Subsidiaries contemplated or entered into by CareTrust, the Operating Partnership or any of the Subsidiaries, (iv) obligation, contingent or otherwise, directly or indirectly incurred by CareTrust,
        the Operating Partnership or any Subsidiary that is material to CareTrust, the Operating Partnership and the Subsidiaries taken as a whole, (v) dividend or distribution of any kind declared, paid or made by CareTrust on any class of its capital
        stock (other than regular quarterly cash dividends), or (vi) Material Adverse Effect.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(nn)&#160;&#160;&#160;&#160;&#160;&#160;&#160; Deloitte &amp; Touche LLP, who has certified the financial statements and supporting schedules of CareTrust incorporated by reference in the Registration Statement, Disclosure Package and
        the Prospectus and who has delivered the comfort letter referred to in Section 6(g) hereof, is an independent public accountant as required by the Exchange Act and is registered with the Public Company Accounting Oversight Board (&#8220;<font style="font-weight: bold; font-style: italic;">PCAOB</font>&#8221;).</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(oo)&#160;&#160;&#160;&#160;&#160;&#160;&#160; [Reserved]</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">14</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(pp)&#160;&#160;&#160;&#160;&#160;&#160; CareTrust maintains a system of internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that complies with the requirements of the Exchange Act and
        has been designed by CareTrust&#8217;s principal executive officer and principal financial officer, or under their supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
        for external purposes in accordance with generally accepted accounting principles. As of the date hereof, except as disclosed in the Registration Statement, the Disclosure Package and the Prospectus, neither CareTrust nor the Operating Partnership
        is aware of (i) any &#8220;significant deficiency&#8221; or &#8220;material weakness&#8221; (in each case, as defined in PCAOB No. 5) in CareTrust&#8217;s internal control over reporting, whether or not subsequently remediated, or (ii) any fraud, whether or not material, that
        involves management or other employees who have a significant role in CareTrust&#8217;s internal control over financial reporting.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(qq)&#160;&#160;&#160;&#160;&#160;&#160;&#160; CareTrust maintains disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) that comply with the requirements of the Exchange Act, which controls and
        procedures (i) are designed to ensure that material information relating to CareTrust, including its consolidated subsidiaries, is made known to CareTrust&#8217;s principal executive officer and its principal financial officer by others within those
        entities, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared and (ii) are effective in all material respects to perform the functions for which they were established, in each case,
        except as disclosed in the Registration Statement, the Disclosure Package and the Prospectus.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(rr)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;There is and has been no failure on the part of CareTrust, the Operating Partnership or any Subsidiary, nor, to the knowledge of CareTrust, the Operating Partnership or any of the
        Subsidiaries, any of their respective directors, members or managers, as applicable, or officers, in their capacities as such, to comply in all material respects with any applicable provision of and the rules and regulations under the
        Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith, including, without limitation, Section 402 related to loans and Sections 302 and 906 related to certifications.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(ss)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Nothing has come to the attention of CareTrust, the Operating Partnership or any of the Subsidiaries that has caused CareTrust, the Operating Partnership or any Subsidiary to believe any
        statistical, demographic, market-related and similar data included in the Registration Statement, the Disclosure Package or the Prospectus is not based on or derived from sources that CareTrust, the Operating Partnership and the Subsidiaries
        believe to be reliable and accurate in all material respects.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(tt)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Common Stock is registered under Section 12(b) of the Exchange Act, and the Shares are listed on the New York Stock Exchange (&#8220;<font style="font-weight: bold; font-style: italic;">NYSE</font>&#8221;),
        and CareTrust has taken no action designed to, or likely to have the effect of, terminating the registration of the Shares under the Exchange Act or delisting the Shares from NYSE, nor has CareTrust received any notification that the Commission or
        NYSE is contemplating terminating such registration or listing. Except as otherwise disclosed in the Prospectus, CareTrust is in material compliance with all applicable listing requirements of NYSE.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(uu)&#160;&#160;&#160;&#160;&#160;&#160;&#160; CareTrust is not, nor upon the issuance and sale of the Shares as herein contemplated and the receipt and application of the net proceeds therefrom as described in the Registration
        Statement, the Disclosure Package and the Prospectus under the caption &#8220;Use Of Proceeds,&#8221; will be, an &#8220;investment company&#8221; or an entity &#8220;controlled&#8221; by an &#8220;investment company&#8221; as such terms are defined in the Investment Company Act of 1940, as
        amended.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">15</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(vv)&#160;&#160;&#160;&#160;&#160;&#160;&#160; None of CareTrust, the Operating Partnership or the Subsidiaries has taken or will take, directly or indirectly, any action designed to or that would constitute or that could reasonably be
        expected to cause or result in the stabilization or manipulation of the price of any security of CareTrust to facilitate the sale or resale of the Shares. None of CareTrust, the Operating Partnership or the Subsidiaries has taken action that would
        directly or indirectly violate any provision of Regulation M under the Exchange Act (&#8220;<font style="font-weight: bold; font-style: italic;">Regulation M</font>&#8221;).</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(ww)&#160;&#160;&#160;&#160;&#160; None of CareTrust, the Operating Partnership or any Subsidiary or any director, officer, agent, employee, affiliate or other person acting on behalf of CareTrust, the Operating Partnership or
        any Subsidiary is aware of or has taken any action, directly or indirectly, that has resulted or would result in a violation by any such person of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the
        &#8220;<font style="font-weight: bold; font-style: italic;">FCPA</font>&#8221;), or any other applicable anti-bribery or anti-corruption law, including, without limitation, any offer, payment, promise to pay or authorization of the payment of any money or
        other property, gift, promise to give or authorization of the giving of anything of value to any &#8220;foreign official&#8221; (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political
        office, in contravention of the FCPA and CareTrust, the Operating Partnership and the Subsidiaries, and their respective affiliates have conducted their businesses in compliance with the FCPA and all other applicable anti-bribery and
        anti-corruption laws and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to ensure, continued compliance therewith.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(xx)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The operations of CareTrust, the Operating Partnership and Subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting
        requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, those of the Bank Secrecy Act, as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and
        Obstruct Terrorism Act of 2001 (USA PATRIOT Act), the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by
        any governmental agency (collectively, &#8220;<font style="font-weight: bold; font-style: italic;">Money Laundering Laws</font>&#8221;) and no action, suit or proceeding by or before any court or governmental or regulatory agency, authority or body or any
        arbitrator involving CareTrust, the Operating Partnership or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of CareTrust, the Operating Partnership or Subsidiaries, is threatened.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(yy)&#160;&#160;&#160;&#160;&#160;&#160;&#160; [Reserved]</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(zz)&#160;&#160;&#160;&#160;&#160;&#160;&#160; None of CareTrust, the Operating Partnership or any Subsidiary or any director, officer, agent, employee, affiliate or other person acting on behalf of CareTrust, the Operating Partnership
        or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Asset Control (&#8220;OFAC&#8221;), nor is CareTrust, the Operating Partnership or any Subsidiary located, organized or resident in a country or territory that
        is the subject to or the target of U.S. sanctions administered by OFAC. None of CareTrust, the Operating Partnership or any Subsidiary will directly or indirectly use any of the proceeds from the sale of Shares in the offering contemplated by this
        Agreement, or lend, contribute or otherwise make available any such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person or territory currently subject to any U.S.
        sanctions administered by OFAC.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">16</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(aaa)&#160;&#160;&#160;&#160;&#160;&#160; There is not a broker, finder or other party that is entitled to receive from CareTrust, the Operating Partnership or any Subsidiary any brokerage or finder&#8217;s fee or other fee or commission
        as a result of any of the transactions contemplated by this Agreement, except for underwriting discounts and commissions payable to the Underwriters in connection with the sale of the Shares pursuant to this Agreement.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(bbb)&#160;&#160;&#160;&#160;&#160; No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) included or incorporated by reference in the Registration
        Statement, the Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(ccc)&#160;&#160;&#160;&#160;&#160; The Common Stock is an &#8220;actively-traded security&#8221; excepted from the requirements of Rule 101 of Regulation M under the Exchange Act by Rule 101(c)(1) thereunder.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(ddd)&#160;&#160;&#160;&#160;&#160; Any certificate signed by any officer of CareTrust or the Operating Partnership and delivered to the Representatives or to counsel for the Underwriters shall be deemed a representation and
        warranty by CareTrust or the Operating Partnership, as the case may be, to each Underwriter as to the matters covered thereby.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(eee)&#160;&#160;&#160;&#160;&#160; Except as otherwise disclosed in the Registration Statement, the Disclosure Package and the Prospectus, to the knowledge of CareTrust, (i)(a) there has been no security breach or other
        compromise of any of the information technology and computer systems, networks, hardware, software, data (including the data of their respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of them),
        equipment or technology of CareTrust, the Operating Partnership or any Subsidiary (collectively, &#8220;<font style="font-weight: bold; font-style: italic;">IT Systems and Data</font>&#8221;) and (b) none of CareTrust, the Operating Partnership or any
        Subsidiary has been notified of, or has any knowledge of, any event or condition that would reasonably be expected to result in, any security breach or other compromise to their IT Systems and Data, except as would not, in the case of this clause
        (i), individually or in the aggregate, have a Material Adverse Effect; (ii) each of CareTrust, the Operating Partnership and the Subsidiaries is presently in compliance with all applicable laws or statutes and all judgments, orders, rules and
        regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from
        unauthorized use, access, misappropriation or modification, except as would not, in the case of this clause (ii), individually or in the aggregate, have a Material Adverse Effect; and (iii) each of CareTrust, Operating Partnership and the
        Subsidiaries has implemented commercially reasonable backup and disaster recovery technology.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">17</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 36pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Sale, Purchase and Delivery of Shares</font>.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On the basis of the representations, warranties and agreements herein contained, but subject to the terms and conditions herein set forth, CareTrust agrees to issue and sell to the several
        Underwriters the Firm Shares. On the basis of the representations, warranties and agreements herein contained, but subject to the conditions hereinafter stated, each Underwriter agrees, severally and not jointly, to purchase from CareTrust at a
        purchase price of $30.72 per share (the &#8220;<font style="font-weight: bold; font-style: italic;">Purchase Price</font>&#8221;) the respective number of Firm Shares set forth opposite the name of such Underwriter on <u>Schedule I</u> hereto.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On the basis of the representations, warranties and agreements contained in this Agreement, and subject to its terms and conditions, CareTrust hereby grants an option to the several
        Underwriters to purchase, severally and not jointly, the Optional Shares or any portion thereof from CareTrust at the Purchase Price. The Representatives may exercise this right on behalf of the Underwriters in whole or from time to time in part by
        giving written notice to CareTrust not later than 30 days after the date of this Agreement. Any exercise notice shall specify the number of Optional Shares to be purchased by the Underwriters and the date on which such shares are to be purchased.
        Unless otherwise agreed by CareTrust, each purchase date of the Optional Shares must be at least three business days after the written notice is given and may not be earlier than the First Delivery Date (as defined below) nor later than ten
        business days after the date of such notice; provided, however, that if notice is received at least one business day prior to the First Delivery Date, the purchase date will be the First Delivery Date. On each Optional Delivery Date, each
        Underwriter agrees, severally and not jointly, to purchase the number of Optional Shares (subject to such adjustments to eliminate fractional shares as the Representatives may determine) that bears the same proportion to the total number of
        Optional Shares to be purchased on such Optional Delivery Date as the number of Firm Shares set forth in <u>Schedule I</u> hereto opposite the name of such Underwriter bears to the total number of Firm Shares to be purchased on the First Delivery
        Date. No Optional Shares shall be sold or delivered unless the Firm Shares previously have been, or simultaneously are, sold and delivered.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The several Underwriters propose to offer the Shares for sale to the public upon the terms and conditions and in the manner set forth in the Prospectus.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Shares to be purchased by each Underwriter hereunder, in book-entry form and in such authorized denominations and registered in such names as the Representatives may request, shall be
        delivered by or on behalf of CareTrust to the Underwriters, through the facilities of The Depository Trust Company, for the accounts of such Underwriters, against payment by or on behalf of the Underwriter of the purchase price therefor by wire
        transfer of federal (same-day) funds to the account specified by CareTrust to the Representatives at least twenty-four hours in advance. The date of such delivery and payment shall be, with respect to the Firm Shares, November 1, 2024 or such other
        time and date as the Representatives and CareTrust may agree upon in writing, and, with respect to the Optional Shares, on the date specified by the Representatives in the written notice given by the Representatives of their election to purchase
        such Optional Shares, or such date as the Representatives and CareTrust may agree upon in writing. Such date for delivery of the Firm Shares is herein called the &#8220;<font style="font-weight: bold; font-style: italic;">First Delivery Date</font>,&#8221;
        such date for delivery of the Optional Shares, if not the First Delivery Date, is herein called an &#8220;<font style="font-weight: bold; font-style: italic;">Optional Delivery Date</font>,&#8221; and each such time and date for delivery is herein called a &#8220;<font style="font-weight: bold; font-style: italic;">Delivery Date</font>.&#8221;</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">18</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Time shall be of the essence, and delivery at the time and place specified pursuant to this Agreement is a further condition of the obligations of the Underwriters hereunder.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Certain Agreements of CareTrust</font>.&#160; CareTrust covenants and agrees with each of the Underwriters:</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To furnish such information as may be required and otherwise to cooperate in qualifying the Shares for offering and sale under (or obtain exemptions from the application of) the securities
        or &#8220;Blue Sky&#8221; laws of such jurisdictions (both domestic and foreign) as the Representatives may designate and to maintain such qualifications (or exemptions) in effect as long as requested by the Representatives for the distribution of the Shares,
        provided that CareTrust shall not be required to qualify as a foreign corporation or to consent to the service of process under the laws of any such state (except service of process with respect to the offering and sale of the Shares).</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If, after the time this Agreement is executed and delivered, it is necessary for a post-effective amendment to the Registration Statement to become effective before the offering of the
        Shares may commence, CareTrust will endeavor to cause such post-effective amendment to become effective as soon as possible and will advise the Representatives promptly and, if requested by the Representatives, will confirm such advice in writing,
        when such post-effective amendment has become effective.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To prepare the Prospectus in a form approved by the Representatives, which approval shall not be unreasonably withheld, delayed or conditioned, and to file such Prospectus pursuant to Rule
        424(b) under the Securities Act not later than the Commission&#8217;s close of business on the second business day following the execution and delivery of this Agreement; during the period beginning on the date hereof and ending on the date, which in the
        opinion of counsel for the Underwriters, a prospectus is no longer required by law to be delivered in connection with the offering and sales of the Shares, to make no further amendment or any supplement to the Registration Statement or Prospectus
        (including any amendment or supplement through incorporation of any report filed under the Exchange Act) which shall be disapproved by the Representatives promptly after reasonable notice thereof, provided that CareTrust may file any information
        required to be filed by Sections 13(a), 13(c) or 15(d) of the Exchange Act upon reasonable notice to the Representatives irrespective of disapproval by the Representatives; to advise the Representatives, promptly after it receives notice thereof,
        of the time when any amendment to the Registration Statement has been filed or becomes effective or any supplement to the Prospectus or any amended Prospectus has been filed and to furnish the Representatives with copies thereof; to file promptly,
        and in any event within the time periods specified, all reports and any definitive proxy or information statements required to be filed by CareTrust pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the
        Prospectus for so long as the delivery of a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Securities Act) is required in connection with the offering or sale of the Shares; to advise the Representatives, promptly
        after it receives notice thereof, of the issuance by the Commission of any stop order or of any order preventing or suspending the use of the Time of Sale Prospectus or the Prospectus or any other prospectus in respect of the Shares, of the
        suspension of the qualification of the Shares for offering or sale in any jurisdiction, of the initiation or threatening of any proceeding for any such purpose or pursuant to Section 8A of the Securities Act, or of any request by the Commission for
        the amending or supplementing of the Registration Statement or Prospectus or for additional information; and, in the event of the issuance of any stop order or of any order preventing or suspending the use of the Time of Sale Prospectus or the
        Prospectus or other prospectus or suspending any such qualification, promptly to use its reasonable best efforts to obtain the withdrawal of such order.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">19</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No later than 5:30 p.m., Eastern time, on the second business day succeeding the date of this Agreement, and from time to time, to furnish the Underwriters with electronic copies of the
        Disclosure Package and the Prospectus in such quantities as the Representatives may reasonably request, and, if the delivery of a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Securities Act) is required at any
        time prior to the expiration of nine months after the time of issue of the Prospectus in connection with the offering or sale of the Shares and if at such time any events shall have occurred as a result of which the Prospectus as then amended or
        supplemented would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when such Prospectus (or in lieu
        thereof, the notice referred to in Rule 173(a) under the Securities Act) is delivered, not misleading, or, if for any other reason it shall be necessary during such period to amend or supplement the Prospectus in order to comply with the Securities
        Act, to notify the Representatives and upon their request to prepare and furnish without charge to each Underwriter and to any dealer in securities as many written and electronic copies as the Representatives may from time to time reasonably
        request of an amended Prospectus or a supplement to the Prospectus which will correct such statement or omission or effect such compliance, and in case any Underwriter is required by law, rule or regulation to deliver a prospectus (or in lieu
        thereof, the notice referred to in Rule 173(a) under the Securities Act) in connection with sales of any of the Shares at any time nine months or more after the time of issue of the Prospectus, upon the request of the Representatives but at the
        expense of such Underwriter, to prepare and deliver to such Underwriter as many written and electronic copies as the Representatives may reasonably request of an amended or supplemented Prospectus complying with Section 10(a)(3) of the Securities
        Act.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To make generally available to its security holders via EDGAR within the required time periods after the effective date of the Registration Statement (as the term &#8220;effective date&#8221; is
        defined in Rule 158(c) under the Securities Act), an earnings statement of CareTrust and its consolidated subsidiaries (which need not be audited) complying with the provisions of Section 11(a) of the Securities Act (including, at the option of
        CareTrust, Rule 158 under the Securities Act).</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">20</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;During the period beginning from the date hereof and continuing to and including the date 45 days after the date of the Prospectus, except as provided hereunder, not to, directly or
        indirectly, offer, sell, contract to sell, pledge or otherwise dispose of (or enter into any transaction or device which is designed to, or could be expected to, result in the disposition of) any shares of Common Stock or any securities that are
        substantially similar to the Common Stock or securities convertible into or exchangeable for Common Stock or any securities that are substantially similar to the Common Stock, or sell or grant options, rights or warrants with respect to any shares
        of Common Stock or any securities that are substantially similar to Common Stock or securities convertible into or exchangeable for Common Stock or any securities that are substantially similar to Common Stock, or publicly announce the intention to
        do any of the foregoing, without the prior written consent of the Representatives, except, in each case (A) the sale of the Shares and (B) the issuance, grant or sale of shares of Common Stock, options to purchase Common Stock, stock units to
        purchase Common Stock or Common Stock issuable upon the exercise of options, stock units or other equity awards granted pursuant to employee benefit or stock incentive plans of CareTrust existing on the date of this Agreement and referred to in the
        Registration Statement.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;During a period of two years from the effective date of the Registration Statement, to deliver or to make available via EDGAR to the Representatives promptly after they become available,
        copies of any reports and financial statements of CareTrust filed with the Commission under the Exchange Act or mailed to its stockholders.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To engage and maintain, at its expense, a registrar and transfer agent for the Shares.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prior to termination of the underwriting syndicate contemplated by this Agreement and during the offering of the Shares by the Underwriters for sale to the public in the manner set forth
        in the Prospectus, not to, and to use its best efforts to cause its officers, directors and affiliates not to, (i) take, directly or indirectly, any action designed to stabilize or manipulate the price of any security of CareTrust, or which may
        cause or result in, or which might in the future reasonably be expected to cause or result in, the stabilization or manipulation of the price of any security of CareTrust, to facilitate the sale or resale of any of the Shares, (ii) sell, bid for,
        purchase or pay anyone any compensation for soliciting purchases of the Shares or (iii) pay or agree to pay any person any compensation for soliciting any order to purchase any other securities of CareTrust.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To comply with all of the provisions of any undertakings in the Registration Statement.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Additional Agreements</font>.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CareTrust represents and agrees that, without the prior consent of the Representatives, it has not made and will not make any offer relating to the Shares that would constitute a &#8220;free
        writing prospectus&#8221; (as defined in Rule 405). Each Underwriter represents and agrees that, without the prior consent of CareTrust and the Representatives, it has not made and will not make any offer relating to the Shares that would be required to
        be filed by CareTrust as a free writing prospectus. Any such free writing prospectus the use of which has been consented to by CareTrust and the Representatives is listed on <u>Schedule II</u> or <u>Schedule III</u> hereto.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CareTrust has complied and will comply with the requirements of Rule 433 under the Securities Act applicable to any Issuer Free Writing Prospectus, including timely filing with the
        Commission or retention where required and legending.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">21</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CareTrust agrees that if at any time following issuance of an Issuer Free Writing Prospectus any event occurred or occurs as a result of which such Issuer Free Writing Prospectus would
        conflict with the information in the Registration Statement, the Time of Sale Prospectus or the Prospectus or would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein,
        in the light of the circumstances then prevailing, not misleading, CareTrust will give prompt notice thereof to the Representatives and, if requested by the Representatives, will prepare and furnish without charge to each Underwriter an Issuer Free
        Writing Prospectus or other document which will correct such conflict, statement or omission. The representation and warranty set forth in the immediately preceding sentence does not apply to statements or omissions made in reliance upon and in
        conformity with written information furnished to CareTrust by an Underwriter expressly for inclusion therein, which information consists solely of the information set forth in <u>Section 7(b)</u> hereof.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each of CareTrust and the Operating Partnership acknowledge and agree that (i) the Underwriters&#8217; research analysts and research departments are required to be independent from their
        respective investment banking divisions and are subject to certain regulations and internal policies and (ii) the Underwriters&#8217; research analysts may hold views and make statements or investment recommendations and/or publish research reports with
        respect to CareTrust, the value of the Common Stock and/or the offering that differ from the views of their respective investment banking divisions. Each of CareTrust and the Operating Partnership hereby waives and releases, to the fullest extent
        permitted by law, any claims that it may have against the Underwriters with respect to any conflict of interest that may arise from the fact that the views expressed by the Underwriters&#8217; independent research analysts and research departments may be
        different from or inconsistent with the views or advice communicated to CareTrust and/or the Operating Partnership by any Underwriter&#8217;s investment banking division. Each of CareTrust and the Operating Partnership acknowledges that each of the
        Underwriters is a full service securities firm and as such, from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity
        securities of CareTrust.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;"><a name="z_Hlk181117399"></a>5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Expenses</font>.&#160; CareTrust will pay or cause to be paid: (a) the fees, disbursements and expenses of CareTrust&#8217;s counsel and
        accountants in connection with the registration of the Shares under the Securities Act and all other expenses in connection with the preparation, printing and filing of the Registration Statement, any preliminary prospectus, any Issuer Free Writing
        Prospectus and the Prospectus and amendments and supplements thereto and the mailing and delivering of copies thereof to the Underwriters and dealers; (b) the cost of printing or producing of a reasonable number of each of any preliminary
        prospectuses, the Prospectus (including any amendments and supplements thereto), any Issuer Free Writing Prospectus and a &#8220;Blue Sky&#8221; Memorandum; (c) all expenses relating to investor presentations or any &#8220;roadshow&#8221; undertaken in connection with
        marketing of the Shares (including electronic roadshows); (d) all expenses in connection with the qualification of the Shares for offering and sale under state securities laws as provided in <u>Section 3(a)</u> hereof, including the reasonable and
        documented fees and disbursements of counsel for the Underwriters in connection with such qualification and in connection with the &#8220;Blue Sky&#8221; Memorandum; (e) if applicable, all fees and expenses in connection with listing the Shares on NYSE; (f)
        the filing fees incident to, and the reasonable and documented fees and disbursements of counsel for the Underwriters in connection with, any required review by FINRA of the terms of the sale of the Shares; (g) the cost of preparing share
        certificates; (h) the cost and charges of any transfer agent or registrar; and (i) all other costs and expenses incident to the performance of its obligations hereunder which are not otherwise specifically provided for in this Section. Except as
        specifically provided in clauses (c) and (e) above, CareTrust shall have no liability for fees or disbursements of counsel for the Underwriters in connection with the transactions contemplated by this Agreement.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">22</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 36pt;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Conditions of the Obligation of the Underwriters</font>.&#160; The obligations of the several Underwriters hereunder shall be subject to the accuracy, when made
        and on each Delivery Date, of the representations and warranties of CareTrust contained herein, to the performance by CareTrust of its obligations hereunder, and to each of the following additional conditions:</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Prospectus shall have been filed with the Commission pursuant to Rule 424(b) within the applicable time period prescribed for such filing by the Securities Act and in accordance with <u>Section
          3(c)</u> hereof; all material required to be filed by CareTrust pursuant to Rule 433(d) under the Securities Act shall have been filed with the Commission within the applicable time period prescribed for such filing by Rule 433. No stop order
        suspending the effectiveness of the Registration Statement or any part thereof shall have been issued and no proceedings for that purpose or pursuant to Section 8A of the Securities Act shall be pending or are, to the best knowledge of CareTrust,
        threatened by the Commission; no stop order suspending or preventing the use of the Prospectus or any Issuer Free Writing Prospectus or any part thereof shall have been issued and no proceedings for that purpose shall be pending or are, to the best
        knowledge of CareTrust, threatened by the Commission; no order suspending the qualification or registration of the Shares under the securities or Blue Sky laws of any jurisdiction shall be in effect and no proceeding for such purpose shall be
        pending before or are, to the best knowledge of CareTrust, threatened by the authorities of any such jurisdiction; all requests for additional information on the part of the Commission shall have been complied with to the reasonable satisfaction of
        the Representatives; and after the date hereof no amendment or supplement to the Registration Statement or the Prospectus relating to the Shares shall have been filed unless a copy thereof was first submitted to the Representatives and the
        Representatives did not object thereto.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Underwriters shall not have discovered and disclosed to CareTrust prior to or on such Delivery Date that (i) the Registration Statement, or any amendment or supplement thereto,
        contains an untrue statement of a fact which, in the opinion of counsel for the Underwriters, is material or omits to state a fact which, in the opinion of counsel for the Underwriters, is material and is required to be stated therein or is
        necessary to make the statements therein not misleading, and (ii) any preliminary prospectus, any Issuer Free Writing Prospectus or the Prospectus, or any amendment or supplement thereto, contains any untrue statement of a fact which, in the
        opinion of counsel for the Underwriters, is material or omits to state a fact which, in the opinion of counsel for the Underwriters, is material and is required to be stated therein or is necessary to make the statements therein, in the light of
        the circumstances under which they were made, not misleading.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;O&#8217;Melveny &amp; Myers LLP, counsel for CareTrust and the Operating Partnership, shall have furnished to the Representatives their written opinion and negative assurance letter, dated such
        Delivery Date, in form and substance satisfactory to the Representatives.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">23</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Kirkland &amp; Ellis LLP, counsel for CareTrust and the Operating Partnership, shall have furnished to the Representatives their written opinion regarding certain tax matters, dated such
        Delivery Date, in form and substance satisfactory to the Representatives.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;DLA Piper LLP (US), special Maryland counsel for CareTrust, shall have furnished to the Representatives their written opinion, dated such Delivery Date, in form and substance satisfactory
        to the Representatives.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Jones Day, counsel for the Underwriters, shall have furnished to the Representatives their written opinion, dated such Delivery Date, in form and substance satisfactory to the
        Representatives.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Underwriters shall have received, on each of the date hereof and each Delivery Date, a letter dated the date hereof or such Delivery Date, as the case may be, in form and substance
        satisfactory to the Representatives, from Deloitte &amp; Touche LLP containing statements and information of the type ordinarily included in accountants&#8217; &#8220;comfort letters&#8221; to underwriters with respect to the financial statements and certain
        financial information of CareTrust, as applicable, contained in the Registration Statement, the Disclosure Package and the Prospectus, provided that the letter shall use a &#8220;cut-off date&#8221; not earlier than the third day prior to such Delivery Date.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CareTrust and the Operating Partnership will, on each Delivery Date, deliver to the Underwriters a certificate of an executive officer of CareTrust and an executive officer of the
        Operating Partnership, dated such Delivery Date, to the effect that:</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The representations and warranties of each of CareTrust and the Operating Partnership, as applicable, in this Agreement are true and correct, as if made on and as of the date thereof and
        provided that any reference therein to the First Delivery Date shall be deemed to refer to the applicable Delivery Date on which such certificate is delivered; and each of CareTrust and the Operating Partnership has complied with all the agreements
        and satisfied all the conditions on its part to be performed or satisfied at or prior to such Delivery Date;</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued and no proceedings for that purpose or pursuant to Section
        8A of the Securities Act have been instituted or are pending or are, to the best knowledge of CareTrust, threatened under the Securities Act;</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160; No stop order suspending or preventing the use of the Prospectus or any Issuer Free Writing Prospectus or any part thereof has been issued and no proceedings for that purpose have been
        instituted or are pending or are, to the best knowledge of CareTrust, threatened under the Securities Act;</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">24</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 108pt;">(iv)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; When the Registration Statement became effective and at all times subsequent thereto up to the date hereof, the Registration Statement and the Prospectus, and any amendments or
        supplements thereto, contained all material information required to be included therein by the Securities Act or the Exchange Act and the applicable rules and regulations of the Commission thereunder, as the case may be, and in all material
        respects conformed to the requirements of the Securities Act or the Exchange Act and the applicable rules and regulations of the Commission thereunder, as the case may be; the Registration Statement, the Disclosure Package and the Prospectus, and
        any amendments or supplements thereto, did not and do not include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances
        under which they were made, not misleading; and, since the effective date of the Registration Statement, there has occurred no event required to be set forth in an amendment or supplemented Prospectus which has not been so set forth; and</div>
      <div>&#160;</div>
      <div style="text-indent: 108pt;">(v)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subsequent to the respective dates as of which information is given in the Registration Statement, the Disclosure Package and Prospectus, except as set forth in the Disclosure Package and
        the Prospectus, there has not been any (a) transaction or event which has a Material Adverse Effect, (b) change in the capitalization of CareTrust, the Operating Partnership or any Subsidiary that is material to CareTrust, the Operating Partnership
        and the Subsidiaries taken as a whole, (c) obligation, contingent or otherwise, directly or indirectly incurred by CareTrust, the Operating Partnership or any Subsidiary that is material to CareTrust, the Operating Partnership and the Subsidiaries
        taken as a whole or (d) dividend or distribution of any kind declared, paid or made by CareTrust on any class of its capital stock.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CareTrust will, on each of the date hereof and each Delivery Date, deliver to the Underwriters a certificate of the Chief Financial Officer of CareTrust, dated the date hereof or such
        Delivery Date, in form and substance satisfactory to the Representatives.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i) Neither CareTrust nor the Operating Partnership nor any of the Subsidiaries shall have sustained since the date of the latest audited financial statements included in the Disclosure
        Package and the Prospectus any loss or interference with its business, otherwise than as set forth in the Disclosure Package and the Prospectus and (ii) since the respective dates as of which information is given in the Prospectus, there shall not
        have been any change in the capitalization of CareTrust or change, or any development or event involving a prospective change, on the condition (financial or otherwise), business, properties, business prospects or results of operations of
        CareTrust, the Operating Partnership and the Subsidiaries, taken as a whole, otherwise than as set forth or contemplated in the Disclosure Package and the Prospectus, the effect of which, in any such case described in clause (i) or (ii), is in the
        judgment of the Representatives so material and adverse as to make it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares being delivered on such Delivery Date on the terms and in the manner contemplated
        in the Disclosure Package and the Prospectus.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;On or after the date hereof, there shall not have occurred any of the following: (i) a suspension or material limitation in trading in securities generally on the NYSE or the Nasdaq Global
        Select Market, (ii) a suspension or material limitation in trading in CareTrust&#8217;s securities on the NYSE, (iii) a general moratorium on commercial banking activities declared by United States federal or New York state authorities or a material
        disruption in commercial banking or securities settlement or clearance services in the United States, (iv) the outbreak or escalation of hostilities involving the United States or the declaration by the United States of a national emergency or war
        or (v) the occurrence of any other calamity or crisis or any change in financial, political or economic conditions in the United States or elsewhere, if the effect of any such event specified in clause (iv) or (v) in the judgment of the
        Representatives makes it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares being delivered on such Delivery Date on the terms and in the manner contemplated in the Disclosure Package and the Prospectus.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">25</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Representatives shall have received from each person listed on <u>Exhibit B</u> hereto an executed lock-up letter agreement substantially to the effect set forth in the form attached
        hereto as <u>Exhibit A</u>.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Each of CareTrust and the Operating Partnership shall have furnished to the Representatives such further information, certificates and documents as the Representatives may reasonably
        request.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">All opinions, certificates, letters and documents mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance
        satisfactory to counsel for the Underwriters.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Indemnification and Contribution</font>.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CareTrust and the Operating Partnership shall, jointly and severally, indemnify and hold harmless each Underwriter, its affiliates, their respective officers, directors, employees and
        agents, and each person, if any, who controls such indemnified party within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, against any losses, claims, damages or liabilities, joint or several, to which such
        Underwriter may become subject, under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) any untrue statement or alleged untrue statement of a
        material fact contained in the Registration Statement, or any amendment or supplement thereto or the omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading, or (ii)
        any untrue statement or alleged untrue statement of a material fact contained in any preliminary prospectus, the Time of Sale Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus or any &#8220;issuer
        information&#8221; filed or required to be filed pursuant to Rule 433(d) under the Securities Act Regulations, or the omission or alleged omission to state therein a material fact necessary to make the statements therein, in the light of the
        circumstances under which they were made, not misleading, and will reimburse each indemnified party for any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending against any such loss,
        claim, damage, liability or action as such expenses are incurred; provided, however, that CareTrust shall not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement
        or alleged untrue statement or omission or alleged omission made in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing
        Prospectus, in reliance upon and in conformity with written information furnished to CareTrust by an Underwriter expressly for inclusion therein, which information consists solely of the information described in <u>Section 7(b)</u> hereof.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">26</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Underwriter, severally and not jointly, shall indemnify and hold harmless CareTrust, the Operating Partnership, their affiliates, their respective officers, directors, employees and
        agents, and each person, if any, who controls CareTrust within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act against any losses, claims, damages or liabilities to which such indemnified party may become subject,
        under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the
        Registration Statement, or any amendment or supplement thereto or the omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii) any untrue statement or alleged
        untrue statement of a material fact contained in any preliminary prospectus, the Time of Sale Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus or any &#8220;issuer information&#8221; filed or required
        to be filed pursuant to Rule 433(d) under the Securities Act Regulations, or the omission or alleged omission to state therein a material fact necessary to make the statements therein, in the light of the circumstances under which they were made,
        not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, any preliminary prospectus, the Time of Sale
        Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, in reliance upon and in conformity with written information furnished to CareTrust by such Underwriter expressly for inclusion therein, and
        will reimburse each indemnified party for any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending against any such loss, claim, damage, liability or action as such expenses are
        incurred. Each of CareTrust and the Operating Partnership hereby acknowledges that the only written information that the Underwriters have furnished to CareTrust and the Operating Partnership expressly for use in the Time of Sale Prospectus and the
        Prospectus consists solely of the statements set forth in the Time of Sale Prospectus and the Prospectus in <a name="z_Hlk181128766"></a>the table in the first paragraph and as set forth in the fifth paragraph, the eleventh paragraph, the twelfth
        paragraph and the fourteenth paragraph under the caption, &#8220;Underwriting.&#8221;</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">27</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Promptly after receipt by an indemnified party under this <u>Section 7</u> of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to
        be made against the indemnifying party under <u>Sections 7(a)</u> or 7<u>(b)</u> hereof, notify the indemnifying party in writing of the commencement thereof; but the omission so to notify the indemnifying party will not relieve it from any
        liability which it may have to any indemnified party otherwise than under <u>Sections 7(a)</u> or 7<u>(b)</u> hereof. In case any such action is brought against any indemnified party and it notifies the indemnifying party of the commencement
        thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it may wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel reasonably satisfactory to such
        indemnified party (who shall not, except with the consent of the indemnified party, be counsel to the indemnifying party), and, except as provided in the following sentence, after notice from the indemnifying party to such indemnified party of its
        election so to assume the defense thereof, the indemnifying party will not be liable to such indemnified party under this Section for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof
        other than reasonable costs of investigation. After notice from the indemnifying party to the indemnified party of the indemnifying party&#8217;s election to assume the defense of such action, the indemnified party shall have the right to employ its own
        counsel in any such action, but the fees and expenses of such counsel shall be at the expense of such indemnified party unless (i) the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel, (ii) if
        the named parties in any such action include both the indemnifying party and the indemnified party and the indemnified party shall have reasonably concluded that there is an actual or potential conflict between the positions of the indemnifying
        party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it or other indemnified parties that are different from or additional to those available to the indemnifying party or
        (iii) the indemnifying party shall not have employed counsel to assume the defense of such action within a reasonable time after notice of commencement thereof, in each of which cases the fees and expenses of such counsel shall be at the expense of
        the indemnifying party (it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel in addition to any local counsel). No indemnifying party shall, without the prior
        written consent of the indemnified party, effect any settlement or compromise of, or consent to the entry of any judgment with respect to, any pending or threatened action or claim in respect of which indemnification or contribution may be sought
        hereunder (whether or not the indemnified party is an actual or potential party to such action or claim) unless such settlement, compromise or judgment (i) includes an unconditional release of the indemnified party from all liability arising out of
        such action or claim and (ii) does not include a statement as to or an admission of fault, culpability or failure to act by or on behalf of any indemnified party. The indemnifying party shall not be liable for any settlement of any proceeding
        effected without its written consent but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such
        settlement or judgment.</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If the indemnification provided for in this Section is unavailable to or insufficient to hold harmless an indemnified party under <u>Sections 7(a)</u> or 7<u>(b)</u> hereof in respect of
        any losses, claims, damages or liabilities (or actions in respect thereof) referred to therein, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or
        liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative benefits received by CareTrust and the Operating Partnership and the Underwriters, respectively, from the offering of the Shares. If, however,
        the allocation provided by the immediately preceding sentence is not permitted by applicable law, then each indemnifying party shall contribute to such amount paid or payable by such indemnified party in such proportion as is appropriate to reflect
        not only the relative benefits but also the relative fault of CareTrust and the Operating Partnership and the Underwriters, respectively, in connection with the statements or omissions which resulted in such losses, claims, damages or liabilities
        (or actions in respect thereof), as well as any other relevant equitable considerations. The relative benefits received by CareTrust and the Operating Partnership and the Underwriters, respectively, shall be deemed to be in the same proportion as
        the total net proceeds from the offering (net of underwriting discounts and commissions but before deducting expenses) received by CareTrust bear to the total underwriting discounts and commissions received by the Underwriters, in each case as set
        forth in the table on the cover page of the Prospectus. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a
        material fact relates to information supplied by CareTrust or the Operating Partnership or the Underwriters and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such untrue statement or omission.
        CareTrust and the Operating Partnership and the Underwriters agree that it would not be just and equitable if contributions pursuant to this <u>Section 7(d)</u> were determined by pro rata allocation or by any other method of allocation which does
        not take account of the equitable considerations referred to above in this <u>Section 7(d)</u>. The amount paid or payable by an indemnified party as a result of the losses, claims, damages or liabilities (or actions in respect thereof) referred
        to above in this <u>Section 7(d)</u> shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim based upon any such untrue or alleged
        untrue statement or omission or alleged omission. Notwithstanding the provisions of this <u>Section 7(d)</u>, no Underwriter shall be required to contribute any amount in excess of the amount by which the underwriting discounts and commissions
        applicable to the Shares purchased by such Underwriter exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of any such untrue or alleged untrue statement or omission or alleged omission. No person
        guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.</div>
      <div style="text-indent: 72pt;"> <br>
         </div>
      <div style="text-indent: 72pt;"> </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">28</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);" noshade="noshade"></div>
      </div>
      <div style="text-indent: 36pt;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Default of the Several Underwriters</font>.&#160; If, on any Delivery Date, any one or more of the several Underwriters shall fail or refuse to purchase Shares
        that it or they have agreed to purchase hereunder on such date, and the aggregate number of Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase does not exceed 10% of the aggregate number of the Shares
        to be purchased on such date, the other Underwriters shall be obligated, severally, in the proportions that the number of shares of Common Stock set forth opposite their respective names on <u>Schedule I</u> hereto bears to the aggregate number of
        shares of Common Stock set forth opposite the names of all such non-defaulting Underwriters, or in such other proportions as may be specified by the Representatives with the consent of the non-defaulting Underwriters, to purchase the Shares which
        such defaulting Underwriter or Underwriters agreed but failed or refused to purchase on such date. If, on any Delivery Date, any one or more of the Underwriters shall fail or refuse to purchase Shares and the aggregate number of Shares with respect
        to which such default occurs exceeds 10% of the aggregate number of Shares to be purchased on such date, and arrangements satisfactory to the Representatives and CareTrust and the Operating Partnership for the purchase of such Shares are not made
        within forty-eight hours after such default, this Agreement shall terminate without liability of any non-defaulting party to any other party except that the provisions of <u>Sections 5</u> and <u>7</u> hereof shall at all times be effective and
        shall survive such termination. In any such case, either the Representatives or CareTrust and the Operating Partnership shall have the right to postpone the Delivery Date but in no event for longer than seven days in order that the required
        changes, if any, to the Registration Statement and the Prospectus or any other documents or arrangements may be effected.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Termination</font>.&#160; The obligations of the Underwriters hereunder may be terminated by the Underwriters by notice given to and received by CareTrust and
        the Operating Partnership prior to delivery of and payment for the Firm Shares or the Optional Shares, respectively, if, prior to that time, any of the events described in <u>Sections 6(j)</u> or <u>6(k)</u> hereof shall have occurred or if the
        Underwriters shall decline to purchase such Shares for any reason permitted under this Agreement other than pursuant to <u>Section 8</u>. In such case, CareTrust shall have no liability hereunder except as provided by <u>Sections 5</u>, <u>7</u>
        and <u>10</u> hereof.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">29</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 36pt;">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-style: italic;">Reimbursement of Underwriters&#8217; Expenses</font>.&#160; If (a) CareTrust shall fail to tender the Shares for delivery to the Underwriters for any reason under
        this Agreement other than a breach by the Underwriters of their representations herein or obligations hereunder or (b) the Underwriters shall decline to purchase the Shares for any reason permitted under this Agreement other than pursuant to <u>Section
          8</u> (including the termination of this Agreement pursuant to <u>Section 9</u> hereof, other than by reason of the occurrence of any event specified in <u>Sections 6(k)(i)</u>, <u>(iii)</u>, <u>(iv)</u> or <u>(v)</u> hereof, but excluding
        the failure of any of the conditions herein to be satisfied as a result of a breach by the Underwriters of their representations herein), CareTrust and the Operating Partnership shall reimburse the Underwriters for the reasonable fees and expenses
        of their counsel and for such other out-of-pocket expenses as shall have been reasonably incurred by them in connection with this Agreement and the proposed purchase of the Shares, and upon demand, CareTrust and the Operating Partnership shall pay
        the full amount thereof to the Underwriters.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-style: italic;">Notices</font>.&#160; All statements, requests, notices and agreements hereunder shall be in writing, and:</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;"><a name="z_Hlk181123471"></a>(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;if to the Underwriters, shall be delivered or sent by mail, telex or facsimile transmission to: Wells Fargo Securities, LLC, 500 West 33rd Street, New York,
        New York 10001, Attention:&#160; Equity Syndicate Department (Fax:&#160; 212-214-5918); BofA Securities, Inc., One Bryant Park, New York, New York 10036, Attention:&#160; Syndicate Department (Email: dg.ecm_execution_services@bofa.com) with a copy to ECM Legal
        (Email: dg.ecm_legal@bofa.com) and J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179 (fax:&#160; (212) 622-8358); Attention Equity Syndicate Desk; and with a copy (which shall not constitute notice) to Jones Day, 901 Lakeside
        Avenue, Cleveland, Ohio 44114, Attention:&#160; Michael J. Solecki, Esq. (Facsimile:&#160; 216-579-0212; Telephone:&#160; 216-586-7103); and</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;if to CareTrust or the Operating Partnership, shall be delivered or sent by mail or facsimile transmission to it at 905 Calle Amanecer, Suite 300, San Clemente, California 92673,
        Attention: William M. Wagner, Chief Financial Officer (Facsimile: 949-540-3002; Telephone: 949-542-3133); with a copy (which shall not constitute notice) to O&#8217;Melveny &amp; Myers LLP, 610 Newport Center Drive, Suite 1700, Newport Beach, CA 92660,
        Attention: Shelly Heyduk (Facsimile: 949-823-6994; Telephone: 949-823-7968).</div>
      <div>&#160;</div>
      <div style="text-indent: 72pt;">Any notice of a change of address or facsimile transmission number must be given by CareTrust or the Underwriters, as the case maybe, in writing at least three days in advance of such change.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-style: italic;">Persons Entitled to Benefit of Agreement</font>.&#160; This Agreement shall inure to the benefit of and be binding upon the Underwriters, CareTrust, the
        Operating Partnership and their respective successors. This Agreement and the terms and provisions hereof are for the sole benefit of only those persons, except that (a) the representations, warranties, indemnities and agreements of CareTrust and
        the Operating Partnership contained in this Agreement shall also be deemed to be for the benefit of the officers and employees of each Underwriter, its affiliates, their respective officers, directors, employees and agents, and each person, if any,
        who controls such indemnified party within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act and (b) the representations and warranties of the Underwriters in this Agreement and the indemnity agreement of the
        Underwriters contained in <u>Section 7(b)</u> hereof shall be deemed to be for the benefit of directors, officers and employees of CareTrust and the Operating Partnership, and any person controlling CareTrust within the meaning of Section 15 of
        the Securities Act or Section 20 of the Exchange Act. Nothing contained in this Agreement is intended or shall be construed to give any person, other than the persons referred to in this <u>Section 12</u>, any legal or equitable right, remedy or
        claim under or in respect of this Agreement or any provision contained herein.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">30</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 36pt;">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-style: italic;">Survival</font>.&#160; The respective indemnities, representations, warranties and agreements of CareTrust and the Operating Partnership and the Underwriters
        contained in this Agreement or made by or on behalf of them, respectively, pursuant to this Agreement, shall survive the delivery of and payment for the Shares and shall remain in full force and effect, regardless of any termination or cancellation
        of this Agreement or any investigation made by or on behalf of any of them or any person controlling any of them.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-style: italic;">Absence of Fiduciary Relationship</font>.&#160; Each of CareTrust and the Operating Partnership acknowledges and agrees that (i) the purchase and sale of the
        Shares pursuant to this Agreement, including the determination of the terms of the offering and any related discounts and commissions, is an arm&#8217;s-length commercial transaction between CareTrust and the Operating Partnership, on the one hand, and
        the several Underwriters, on the other, (ii) in connection therewith and with the process leading to such transaction, each Underwriter is acting solely as a principal and not the agent or fiduciary of CareTrust or the Operating Partnership, or
        their respective security holders, creditors, employees or any other party, (iii) no Underwriter has assumed, nor will it assume, any advisory or fiduciary responsibility in favor of CareTrust or the Operating Partnership with respect to the
        offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter or its affiliates has advised or is currently advising CareTrust or the Operating Partnership on other matters) or any other obligation to
        CareTrust or Operating Partnership except the obligations expressly set forth in this Agreement, (iv) the Underwriters and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of
        CareTrust and the Operating Partnership and (v) the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated by this Agreement and CareTrust and the Operating Partnership consulted its
        own legal, accounting, regulatory, tax and financial advisors to the extent it deemed appropriate. Each of CareTrust and the Operating Partnership agrees that it will not claim that the Underwriters, or any of them, has rendered advisory services
        of any nature or respect, or owes a fiduciary or similar duty to CareTrust or the Operating Partnership, in connection with such transaction or the process leading thereto.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">15.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-style: italic;">Governing Law</font>.&#160; THIS AGREEMENT AND ANY DISPUTE, CLAIM OR CONTROVERSY ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED
        IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. Each party hereto hereby irrevocably submits for purposes of any action arising from this Agreement brought by the other party hereto to the jurisdiction of the courts of New York State located
        in the Borough of Manhattan and the U.S. District Court for the Southern District of New York.</div>
      <div>&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" class="BRPFPageNumber">31</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-indent: 36pt;"><a name="z_Hlk136634191"></a>16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-style: italic;">Recognition of U.S. Special Resolution Regimes</font>. (i) In the event that any Underwriter that is a Covered Entity becomes
        subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be
        effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.</div>
      <div>&#160;</div>
      <div style="text-indent: 40.5pt;">(ii) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under
        this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the
        United States or a state of the United States.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">As used in this Section 16, the term &#8220;BHC Act Affiliate&#8221; has the meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k); the term &#8220;Covered Entity&#8221;
        means any of the following: (i) a &#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (ii) a &#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or
        (iii) a &#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b); the term &#8220;Default Right&#8221; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or
        382.1, as applicable; and the term &#8220;U.S. Special Resolution Regime&#8221; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act
        and the regulations promulgated thereunder.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">17.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-style: italic;">Counterparts</font>.&#160; This Agreement may be executed in one or more counterparts and, if executed in more than one counterpart, the executed counterparts
        shall each be deemed to be an original but all such counterparts shall together constitute one and the same instrument.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">18.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-style: italic;">Headings</font>.&#160; The headings herein are inserted for convenience of reference only and are not intended to be part of, or to affect the meaning or
        interpretation of, this Agreement.</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">19.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-style: italic;">Waiver of Jury Trial</font>. Each of CareTrust, the Operating Partnership and the Underwriters hereby irrevocably waives any right it may have to a trial
        by jury in respect of any claim based upon or arising out of this Agreement or the transactions contemplated hereby or thereby.</div>
      <div style="text-indent: 36pt;"> <br>
         </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div>
        <div style="text-indent: 36pt;">
          <div style="text-indent: 72pt;">If the foregoing correctly sets forth the agreement between CareTrust and the Operating Partnership and the Underwriters, please indicate your acceptance in the space provided for that purpose
            below.</div>
          <div>&#160;</div>
          <table id="z87244e92d69b4aec9b64002b6d1019b3" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
                <td style="vertical-align: top;" colspan="3">
                  <div>Very truly yours,</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
                <td style="vertical-align: top;" colspan="3">&#160;</td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
                <td style="vertical-align: top;" colspan="3">
                  <div style="font-weight: bold;">CARETRUST REIT, INC.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="vertical-align: top;" colspan="2">&#160;</td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
                  <div>By:</div>
                </td>
                <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                  <div>/s/ William M. Wagner</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="width: 5%; vertical-align: top;">
                  <div>Name:</div>
                </td>
                <td style="width: 42%; vertical-align: top;">
                  <div>William M. Wagner</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="width: 5%; vertical-align: top;">
                  <div>Title:</div>
                </td>
                <td style="width: 42%; vertical-align: top;">
                  <div>Chief Financial Officer and Treasurer</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="vertical-align: top;" colspan="2">&#160;</td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
                <td style="vertical-align: top;" colspan="3">
                  <div style="font-weight: bold;">CTR PARTNERSHIP, L.P.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
                <td style="vertical-align: top;" colspan="3">&#160;</td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
                <td style="width: 3%; vertical-align: top;">
                  <div>By:</div>
                </td>
                <td style="vertical-align: top;" colspan="2">
                  <div>CareTrust GP, LLC, its general partner</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="vertical-align: top;" colspan="2">&#160;</td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
                <td style="width: 3%; vertical-align: top;">
                  <div>By:</div>
                </td>
                <td style="vertical-align: top;" colspan="2">
                  <div>CareTrust REIT, Inc., its sole member</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="width: 5%; vertical-align: top;">&#160;</td>
                <td style="width: 42%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
                  <div>By:</div>
                </td>
                <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                  <div>/s/ William M. Wagner</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="width: 5%; vertical-align: top;">
                  <div>Name:</div>
                </td>
                <td style="width: 42%; vertical-align: top;">
                  <div>William M. Wagner</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="width: 5%; vertical-align: top;">
                  <div>Title:</div>
                </td>
                <td style="width: 42%; vertical-align: top;">
                  <div>Chief Financial Officer and Treasurer</div>
                </td>
              </tr>

          </table>
          <div>
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 12pt;"> <font style="font-size: 10pt;"><br>
              </font> </div>
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">[<font style="font-style: italic;">Signature Page to Underwriting Agreement</font>]</div>
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 12pt;"> <font style="font-size: 10pt;"><br>
              </font></div>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <table id="z68b55975cee34e3ea18b0d5a4628c622" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

              <tr>
                <td style="vertical-align: top;" colspan="3">
                  <div>Accepted and agreed by:</div>
                </td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align: top;" colspan="3">&#160;</td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align: top;" colspan="3">
                  <div>WELLS FARGO SECURITIES, LLC</div>
                </td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="vertical-align: top;" colspan="2">
                  <div>Acting as Representative of the</div>
                </td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="vertical-align: top;" colspan="2">
                  <div>Several Underwriters named</div>
                </td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="vertical-align: top;" colspan="2">
                  <div>in attached Schedule I</div>
                </td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="vertical-align: top;" colspan="2">&#160;</td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
                  <div>By</div>
                </td>
                <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                  <div>/s/ Rohit Mehta</div>
                </td>
                <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="width: 5%; vertical-align: top;">
                  <div>Name:</div>
                </td>
                <td style="width: 42%; vertical-align: top;">
                  <div>Rohit Mehta</div>
                </td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="width: 5%; vertical-align: top;">
                  <div>Title:</div>
                </td>
                <td style="width: 42%; vertical-align: top;">
                  <div>Executive Director</div>
                </td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>

          </table>
          <div> <br>
             </div>
          <div>
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">[<font style="font-style: italic;">Signature Page to Underwriting Agreement</font>]</div>
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;"> <br>
            </div>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <table id="z3c7cbb268a8e497ea9185f910b2a188b" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

              <tr>
                <td style="vertical-align: top;" colspan="3">
                  <div>Accepted and agreed by:</div>
                </td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align: top;" colspan="3">&#160;</td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align: top;" colspan="3">
                  <div>BOFA SECURITIES, INC.</div>
                </td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="vertical-align: top;" colspan="2">
                  <div>Acting as Representative of the</div>
                </td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="vertical-align: top;" colspan="2">
                  <div>Several Underwriters named</div>
                </td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="vertical-align: top;" colspan="2">
                  <div>in attached Schedule I</div>
                </td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="vertical-align: top;" colspan="2">&#160;</td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
                  <div>By:</div>
                </td>
                <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                  <div>/s/ Gray Hampton</div>
                </td>
                <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="width: 5%; vertical-align: top;">
                  <div>Name:</div>
                </td>
                <td style="width: 42%; vertical-align: top;">
                  <div>Gray Hampton</div>
                </td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="width: 5%; vertical-align: top;">
                  <div>Title:</div>
                </td>
                <td style="width: 42%; vertical-align: top;">
                  <div>Vice Chairman</div>
                </td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>

          </table>
          <div><br>
             </div>
          <div>
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">[<font style="font-style: italic;">Signature Page to Underwriting Agreement</font>]</div>
            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;"> <br>
            </div>
          </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <table id="z5cc263c7a107431eb11c2b5d67b26f4d" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

              <tr>
                <td style="vertical-align: top;" colspan="3">
                  <div>Accepted and agreed by:</div>
                </td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align: top;" colspan="3">&#160;</td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="vertical-align: top;" colspan="3">
                  <div>J.P. MORGAN SECURITIES LLC</div>
                </td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="vertical-align: top;" colspan="2">
                  <div>Acting as Representative of the</div>
                </td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="vertical-align: top;" colspan="2">
                  <div>Several Underwriters named</div>
                </td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="vertical-align: top;" colspan="2">
                  <div>in attached Schedule I</div>
                </td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="vertical-align: top;" colspan="2">&#160;</td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
                  <div>By:</div>
                </td>
                <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                  <div>/s/ Samantha Carter</div>
                </td>
                <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="width: 5%; vertical-align: top;">
                  <div>Name:</div>
                </td>
                <td style="width: 42%; vertical-align: top;">
                  <div>Samantha Carter</div>
                </td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 3%; vertical-align: top;">&#160;</td>
                <td style="width: 5%; vertical-align: top;">
                  <div>Title:</div>
                </td>
                <td style="width: 42%; vertical-align: top;">
                  <div>VP</div>
                </td>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
              </tr>

          </table>
          <div> <br>

            <div style="text-align: center; font-family: 'Times New Roman',Times,serif;">[<font style="font-style: italic;">Signature Page to Underwriting Agreement</font>]</div>
            <br>
             </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: right; font-weight: bold;"><u>SCHEDULE I</u></div>
          <div>&#160;</div>
          <table id="z4ef8ddc42f0a443e8314511f3bb56e77" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 77%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="font-weight: bold;">Underwriter</div>
                </td>
                <td style="width: 3.44%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td style="width: 20%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="text-align: center; font-weight: bold;">Number of </div>
                  <div style="text-align: center; font-weight: bold;">Firm Shares to be </div>
                  <div style="text-align: center; font-weight: bold;">Purchased</div>
                </td>
              </tr>
              <tr>
                <td style="width: 77%; vertical-align: top;">&#160;</td>
                <td style="width: 3.44%; vertical-align: top;">&#160;</td>
                <td style="width: 20%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 77%; vertical-align: top;">
                  <div>Wells Fargo Securities, LLC</div>
                </td>
                <td style="width: 3.44%; vertical-align: top;">&#160;</td>
                <td style="width: 20%; vertical-align: top;">
                  <div style="text-align: center;">2,691,000</div>
                </td>
              </tr>
              <tr>
                <td style="width: 77%; vertical-align: top;">
                  <div>BofA Securities, Inc.</div>
                </td>
                <td style="width: 3.44%; vertical-align: top;">&#160;</td>
                <td style="width: 20%; vertical-align: top;">
                  <div style="text-align: center;">2,553,000</div>
                </td>
              </tr>
              <tr>
                <td style="width: 77%; vertical-align: top;">
                  <div>J.P. Morgan Securities LLC</div>
                </td>
                <td style="width: 3.44%; vertical-align: top;">&#160;</td>
                <td style="width: 20%; vertical-align: top;">
                  <div style="text-align: center;">2,622,000</div>
                </td>
              </tr>
              <tr>
                <td style="width: 77%; vertical-align: top;">
                  <div>BMO Capital Markets Corp.</div>
                </td>
                <td style="width: 3.44%; vertical-align: top;">&#160;</td>
                <td style="width: 20%; vertical-align: top;">
                  <div style="text-align: center;">2,139,000</div>
                </td>
              </tr>
              <tr>
                <td style="width: 77%; vertical-align: top;">
                  <div>KeyBanc Capital Markets Inc.</div>
                </td>
                <td style="width: 3.44%; vertical-align: top;">&#160;</td>
                <td style="width: 20%; vertical-align: top;">
                  <div style="text-align: center;">2,139,000</div>
                </td>
              </tr>
              <tr>
                <td style="width: 77%; vertical-align: top;">
                  <div>Huntington Securities, Inc.</div>
                </td>
                <td style="width: 3.44%; vertical-align: top;">&#160;</td>
                <td style="width: 20%; vertical-align: top;">
                  <div style="text-align: center;">1,035,000</div>
                </td>
              </tr>
              <tr>
                <td style="width: 77%; vertical-align: top;">
                  <div>Raymond James &amp; Associates, Inc.</div>
                </td>
                <td style="width: 3.44%; vertical-align: top;">&#160;</td>
                <td style="width: 20%; vertical-align: top;">
                  <div style="text-align: center;">621,000</div>
                </td>
              </tr>
              <tr>
                <td style="width: 77%; vertical-align: top;">&#160;</td>
                <td style="width: 3.44%; vertical-align: top;">&#160;</td>
                <td style="width: 20%; vertical-align: top; text-align: center;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 77%; vertical-align: top;">
                  <div style="font-weight: bold; margin-left: 27pt;">Total</div>
                </td>
                <td style="width: 3.44%; vertical-align: top;">&#160;</td>
                <td style="width: 20%; vertical-align: top;">
                  <div style="text-align: center;">13,800,000</div>
                </td>
              </tr>

          </table>
          <div><br>
             </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: right; font-weight: bold;"><u>SCHEDULE II</u></div>
          <div>&#160;</div>
          <div>Materials other than the Time of Sale Prospectus that comprise the Disclosure Package:</div>
          <div>&#160;</div>
          <div>Price to public $32.00 per share.</div>
          <div>&#160;</div>
          <div>Offering size of 13,800,000 Firm Shares (not including Optional Shares that may be purchased at the option of the Underwriters)</div>
          <div>&#160;</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: right; font-weight: bold;"><u>SCHEDULE III</u></div>
          <div>&#160;</div>
          <div>Issuer Free Writing Prospectuses not included in the Disclosure Package:</div>
          <div>&#160;</div>
          <div>Net Road Show presentation, dated October 30, 2024.</div>
          <div>&#160;</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: right; font-weight: bold;"><u>Exhibit A</u></div>
          <div>&#160;</div>
          <div style="text-align: center; font-weight: bold;">FORM OF LOCK-UP LETTER AGREEMENT</div>
          <div>&#160;</div>
          <div style="text-align: right;">October ___, 2024</div>
          <div>&#160;</div>
          <div>Wells Fargo Securities, LLC</div>
          <div>&#160;BofA Securities, Inc.</div>
          <div>&#160;J.P. Morgan Securities LLC</div>
          <div>&#160;As Representatives of the several Underwriters</div>
          <div>&#160;</div>
          <div>c/o Wells Fargo Securities, LLC</div>
          <div>500 West 33rd Street, 14th Floor</div>
          <div>New York, New York 10001</div>
          <div><br>
             </div>
          <div>&#160;</div>
          <div>Ladies and Gentlemen:</div>
          <div>&#160;</div>
          <div style="text-indent: 36pt;">The undersigned understands that you, as Representatives (collectively, the &#8220;Representatives&#8221;) of the several underwriters (collectively, the &#8220;Underwriters&#8221;), propose to enter into an Underwriting
            Agreement (the &#8220;Underwriting Agreement&#8221;) with CareTrust REIT, Inc., a Maryland corporation (&#8220;CareTrust&#8221;), and CTR Partnership, L.P., a Delaware limited partnership (the &#8220;Operating Partnership&#8221;), providing for a public offering (the &#8220;Offering&#8221;)
            of shares of the common stock of CareTrust, par value $0.01 per share (the &#8220;Common Stock&#8221;). The undersigned recognizes that the Offering will be of benefit to the undersigned and will benefit CareTrust and the Operating Partnership. The
            undersigned acknowledges that CareTrust, the Operating Partnership, you and the other Underwriters will proceed with the Offering in reliance on this Lock-Up Letter Agreement.</div>
          <div>&#160;</div>
          <div style="text-indent: 36pt;">In consideration of the foregoing, the undersigned hereby agrees that the undersigned will not (and will cause any spouse or immediate family member of the spouse or the undersigned living in the
            undersigned&#8217;s household not to), without the prior written consent of the Representatives (which consent may be withheld in their sole discretion), directly or indirectly, sell, offer, contract or grant any option to sell (including, without
            limitation, any short sale), pledge, transfer, establish an open &#8220;put equivalent position&#8221; within the meaning of Rule 16a-1(h) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise dispose of any shares of
            Common Stock, options or warrants to acquire shares of Common Stock, or securities exchangeable or exercisable for or convertible into shares of Common Stock currently or hereafter owned either of record or beneficially (as defined in Rule
            13d-3 under the Exchange Act) by the undersigned (or such spouse or family member), or publicly announce an intention to do any of the foregoing, for a period commencing on the initial filing date of the preliminary prospectus supplement used
            to sell the shares of Common Stock in the Offering filed pursuant to Rule 424(b) of the Securities Act of 1933, as amended (the &#8220;Act&#8221;), and continuing through the close of trading on the date 45 days after the date of the final prospectus
            supplement used to sell the shares of Common Stock in the Offering filed pursuant to Rule 424(b) under the Act (the &#8220;Lock-Up Period&#8221;). The foregoing sentence shall not apply to:</div>
          <div>&#160;</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;transfers of shares of Common Stock or any security convertible into or exercisable or exchangeable for shares of Common Stock (i) as a bona fide gift, including to charitable
            organizations, or by will or intestacy, (ii) to the spouse, parent, sibling, child or grandchild of the undersigned or any other person with whom the undersigned has a relationship by blood, marriage or adoption not more remote than first
            cousin (each, &#8220;an immediate family member&#8221;) or to a trust, or other entity formed for estate planning purposes, formed for the benefit of the undersigned or of an immediate family member of the undersigned, (iii) if the undersigned is a
            corporation or partnership or limited liability company or other business entity, to another corporation, partnership, limited liability company or other business entity that controls, is controlled by or is under common control with the
            undersigned, (iv) if the undersigned is a trust, to a trustor or beneficiary of the trust or (v) not involving a change in beneficial ownership; provided that in the case of any transfer or distribution pursuant to this clause (a), (A) each
            transferee, donee or distributee shall sign and deliver a lock-up agreement substantially in the form of this Lock-Up Letter Agreement and (B) no filing under the Exchange Act, reporting a reduction of beneficial ownership of shares of Common
            Stock, shall be required (other than a filing on Form 5 required and filed after the expiration of the Lock-Up Period or, in the case of (i), (ii), (iii) or (iv) above, a filing on Form 4 if required to be made during the Lock-Up Period as a
            result of any applicable transfer) or shall be voluntarily made during the Lock-Up Period;</div>
          <div>&#160;</div>
          <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;distributions of shares of Common Stock or any security convertible into or exercisable or exchangeable for shares of Common Stock to limited partners or stockholders of the
            undersigned; provided that in the case of any transfer or distribution pursuant to this clause (c), (A) each donee or distributee shall sign and deliver a lock-up agreement substantially in the form of this Lock-Up Letter Agreement and (B) no
            filing under the Exchange Act, reporting a reduction in beneficial ownership of shares of Common Stock, shall be required or shall be voluntarily made during the Lock-Up Period;</div>
          <div>&#160;</div>
          <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the receipt by the undersigned from CareTrust of shares of Common Stock upon the vesting of stock units or stock awards issued pursuant to CareTrust&#8217;s equity incentive plans or the
            transfer of shares of Common Stock or any securities convertible into shares of Common Stock to CareTrust upon a vesting event of CareTrust&#8217;s securities or upon the exercise of options or warrants to purchase CareTrust&#8217;s securities (including
            settlement of restricted stock units), in each case on a &#8220;cashless&#8221; or &#8220;net exercise&#8221; basis or to cover tax withholding obligations of the undersigned in connection with such vesting or exercise, provided that any related filing under the
            Exchange Act required to be made during the Lock-Up Period shall indicate that such filing is being made in connection with a disposition to CareTrust to satisfy tax withholding requirements;</div>
          <div>&#160;</div>
          <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the establishment of a written trading plan pursuant to Rule 10b5-1 under the Exchange Act during the Lock-Up Period for the transfer of shares of Common Stock, provided that (A) such
            plan does not provide for the transfer of shares of Common Stock during the Lock-Up Period and (B) no public announcement or filing under the Exchange Act shall be made during the Lock-Up Period by or on behalf of the undersigned or CareTrust
            regarding the establishment of such plan;</div>
          <div>&#160;</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-indent: 72pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;if the undersigned is an individual, the transfer of shares of Common Stock or any security convertible into or exercisable or exchangeable for shares of Common Stock that occurs by
            operation of law pursuant to a qualified domestic order or in connection with a divorce settlement, provided that the undersigned shall use reasonable best efforts to cause the transferee to sign and deliver a lock-up agreement substantially in
            the form of this Lock-Up Letter Agreement, and provided further, that any filing under the Exchange Act that is required to be made during the Lock-Up Period as a result of such transfer, states (unless prohibited by law) that such transfer has
            occurred by operation of law and that such transfer is pursuant to a qualified domestic order or in connection with a divorce settlement, as applicable; and</div>
          <div>&#160;</div>
          <div style="text-indent: 72pt;">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any transfer of shares of Common Stock or any security convertible into or exercisable or exchangeable for shares of Common Stock to a bona fide third party pursuant to a tender offer,
            merger, consolidation or other similar transaction made to all holders of the Common Stock involving a &#8220;change of control&#8221; (as defined below) of CareTrust following the Offering; provided that in the event that the tender offer, merger,
            consolidation or other such transaction is not completed, the shares of Common Stock owned by the undersigned shall remain subject to the terms of this Lock-Up Letter Agreement. For purposes of this clause (f), &#8220;change of control&#8221; shall mean
            the consummation of any bona fide third party tender offer, merger, consolidation or other similar transaction the result of which is that any &#8220;person&#8221; (as defined in Section 13(d)(3) of the Exchange Act), or group of persons, other than
            CareTrust, becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 of the Exchange Act) of 50% of total voting power of the voting stock of the CareTrust.</div>
          <div>&#160;</div>
          <div style="text-indent: 36pt;">The undersigned agrees and consents to the entry of stop transfer instructions with CareTrust&#8217;s transfer agent and registrar against the transfer of shares of Common Stock or securities convertible
            into or exchangeable or exercisable for shares of Common Stock held by the undersigned except in compliance with the foregoing restrictions.</div>
          <div>&#160;</div>
          <div style="text-indent: 36pt;">If for any reason the Offering or the Underwriting Agreement (other than the provisions thereof that survive termination) is terminated prior to the First Delivery Date (as defined in the
            Underwriting Agreement) pursuant to the provisions thereof, then the agreements set forth herein shall likewise be terminated and the undersigned shall be released from all obligations hereunder.</div>
          <div>&#160;</div>
          <div style="text-indent: 36pt;">This Lock-Up Letter Agreement is irrevocable and will be binding on the undersigned and the respective successors, heirs, personal representatives, and assigns of the undersigned.</div>
          <div>&#160;</div>
          <div style="text-indent: 36pt;">The undersigned acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have the Underwriters solicited any action from the undersigned with
            respect to the Offering of the Common Stock and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate. The undersigned further acknowledges and agrees that, although
            the Representatives may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection with the Offering, the Representatives and the other Underwriters are not making a recommendation to you to
            enter into this Lock-Up Letter Agreement, and nothing set forth in such disclosures is intended to suggest that the Representatives or any Underwriter is making such a recommendation</div>
          <div>&#160;</div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-indent: 36pt;">THIS LOCK-UP LETTER AGREEMENT AND ANY DISPUTE, CLAIM OR CONTROVERSY ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW
            YORK. The undersigned hereby irrevocably submits for purposes of any action arising from this Agreement brought by the Underwriters to the jurisdiction of the courts of New York State located in the Borough of Manhattan and the U.S. District
            Court for the Southern District of New York.</div>
          <div>&#160;</div>
          <table id="z1506fd21f836485292f232f03db39337" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

              <tr>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
                <td style="vertical-align: top;" colspan="2">
                  <div>Very truly yours,</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
                <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">&#160;</td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
                <td style="width: 5%; vertical-align: top;">
                  <div>Name:</div>
                </td>
                <td style="width: 45%; vertical-align: top;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top;">&#160;</td>
                <td style="width: 5%; vertical-align: top;">
                  <div>Title:</div>
                </td>
                <td style="width: 45%; vertical-align: top;">&#160;</td>
              </tr>

          </table>
          <div><br>
             </div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
          </div>
          <div style="text-align: right; font-weight: bold;"><u>Exhibit B</u></div>
          <div>&#160;</div>
          <div style="font-family: 'Times New Roman',Times,serif; font-weight: bold;"><font style="font-family: 'Times New Roman';"><u>Persons to Execute Lock-Up Letter Agreements</u>:</font></div>
          <div>&#160;</div>
          <div>1. James B. Callister</div>
          <div>&#160;</div>
          <div>2. David M. Sedgwick</div>
          <div>&#160;</div>
          <div>3. William M. Wagner</div>
          <div>&#160;</div>
          <div>4. Diana M. Laing</div>
          <div>&#160;</div>
          <div>5. Anne Olson</div>
          <div>&#160;</div>
          <div>6. Spencer G. Plumb</div>
          <div>&#160;</div>
          <div>7. Careina D. Williams</div>
          <br>
           </div>
      </div>
      <div>&#160;</div>
      <hr style="height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); text-align: center; margin-left: auto; margin-right: auto; border: medium none;" align="center" noshade="noshade"></div>
  </div>


</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ny20037824x3_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.9.1.5252
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 5.1</font><br>
    </div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 66%; vertical-align: top;">
            <div style="text-align: left;"><img width="120" height="70" src="ny20037824x3_logo.jpg"></div>
          </td>
          <td style="width: 34%; vertical-align: top;">
            <div style="font-family: 'Times New Roman',Times,serif; font-size: 8pt; font-weight: bold; text-align: left;">DLA Piper LLP (US)</div>
            <div style="font-family: 'Times New Roman',Times,serif; font-size: 8pt; text-align: left;">650 S Exeter Street</div>
            <div style="font-family: 'Times New Roman',Times,serif; font-size: 8pt; text-align: left;">Suite 1100</div>
            <div style="font-family: 'Times New Roman',Times,serif; font-size: 8pt; text-align: left;">Baltimore, Maryland&#160; 21202</div>
            <div style="font-family: 'Times New Roman',Times,serif; font-size: 8pt; text-align: left;">www.dlapiper.com</div>
            <div style="font-family: 'Times New Roman',Times,serif; font-size: 8pt; text-align: left;"> <br>
            </div>
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-size: 8pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">T</font><font style="font-size: 8pt;">&#160;&#160;
                410.580.3000</font></div>
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;"><font style="font-size: 8pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">F</font><font style="font-size: 8pt;">&#160;&#160;
                410.580.3001</font></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: -188.65pt; margin-left: 188.65pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">November 1, 2024</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">CareTrust REIT, Inc.</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">905 Calle Amanecer, Suite 300</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">San Clemente, CA 92673</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><u>Offering of Common Stock</u></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: -0.45pt; margin-left: 0.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ladies and Gentlemen:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have served as special Maryland counsel to CareTrust REIT, Inc., a Maryland corporation (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Company</u></font>&#8221;),<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</font>and have been requested to render this opinion letter in connection with the registration
      under the Securities Act of 1933, as amended (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Securities Act</u></font>&#8221;), pursuant to the automatic shelf registration statement of the Company on Form S-3
      (Registration No. 333- 269998) (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Registration Statement</u></font>&#8221;), prepared and filed by the Company on February 24, 2023 with the Securities and Exchange
      Commission (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Commission</u></font>&#8221;), including the base prospectus included therein at the time the Registration Statement became effective (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Base Prospectus</u></font>&#8221;), and the preliminary prospectus supplement, dated October 30, 2024, and filed by the Company with the Commission on October 30, 2024, pursuant to
      Rule 424(b)(5) under the Securities Act (together with the Base Prospectus, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Preliminary Prospectus</u></font>&#8221;), and the final prospectus supplement, dated October
      30, 2024, and filed by the Company with the Commission on October 31, 2024 pursuant to Rule 424(b)(5) under the Securities Act (together with the Base Prospectus, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Prospectus</u></font>&#8221;),
      of the offering by the Company of an aggregate of (i) 13,800,000 shares (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Firm Shares</u></font>&#8221;) of common stock, par value $0.01 per share, of the Company (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Common Stock</u></font>&#8221;) and (ii) an additional 2,070,000 shares of Common Stock (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Optional
          Shares</u></font>,&#8221; and together with the Firm Shares, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Shares</u></font>&#8221;) pursuant to the option to purchase additional shares described in the Underwriting
      Agreement, dated as of October 30, 2024 (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Underwriting Agreement</u></font>&#8221;), by and among the Company and CTR Partnership, L.P., a Delaware limited partnership (the
      &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Operating Partnership</u></font>&#8221;), on the one hand, and Wells Fargo Securities, LLC, BofA Securities, Inc. and J.P. Morgan Securities LLC (collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Representatives</u></font>&#8221;), as representatives of the several underwriters named on <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Schedule
          I</u></font> to the Underwriting Agreement (collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Underwriters</u></font>&#8221;), on the other hand. This opinion letter is being provided at your request in
      connection with the filing by the Company with the Commission of a Current Report on Form 8-K on the date hereof (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Form 8-K</u></font>&#8221;), and supplements our opinion,
      dated February 24, 2023, previously filed as Exhibit 5.2 to the Registration Statement. Capitalized terms used but not defined herein shall have the meanings specified in the Underwriting Agreement.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In connection with our representation of the Company, and as a basis for the opinions hereinafter set forth, we have examined originals,
      or copies certified or otherwise identified to our satisfaction, of the following documents:</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z6337906f96724dad84545d523c3bda00" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the Registration Statement;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z7c43db94194a4d1fbb582aed29b20eac" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the Underwriting Agreement;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zc67d5647d1aa41baa06eef982f25f56d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(c)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the Preliminary Prospectus;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z85e1b637bce145d6b584f41500fc894f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the Prospectus;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">CareTrust REIT, Inc.</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">November 1, 2024</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Page 2</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zaac9989332ca4da9979cad9146f10f27" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(e)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the Articles of Amendment and Restatement of the Company as filed with the State Department of Assessments and Taxation of the State of Maryland (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>SDAT</u></font>&#8221;) on and effective as of May 13, 2014, as amended by the Articles of Amendment to Articles of Amendment and Restatement of the Company as filed with
              the SDAT on and effective as of May 30, 2018 (collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Charter</u></font>&#8221;);</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zbcada42f3794467696f3cd4a3ea5154a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(f)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the Company&#8217;s Amended and Restated Bylaws, as certified by the Secretary of the Company, as of the date hereof;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z8f8c95d48c344606abd3560dae6a7187" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(g)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">resolutions of the Board of Directors of the Company (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Board Resolutions</u></font>&#8221;)
              relating to the authorization and issuance of the Shares and the authorization of the Underwriting Agreement and the appointment and establishment of a Securities Committee of the Board of Directors and the transactions contemplated thereby,
              certified by an officer of the Company;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z4ad46b08bf8c4be48e055db6694cd1e4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(h)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">resolutions of the Securities Committee of the Board of Directors of the Company (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Securities
                  Committee Resolutions</u></font>&#8221; and together with the Board Resolutions, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Resolutions</u></font>&#8221;) relating to the authorization of the issuance and
              sale of the Shares, the selection of the Underwriters and approval of the Underwriting Agreement;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z8ef93cd1bdd647359091791bddc0c52c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(i)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">an executed copy of the certificate of an officer of the Company, dated as of the date hereof, as to certain factual matters;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="za4be8396be6840849d447af5b51d3062" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(j)</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the certificate of the SDAT as to the existence and good standing of the Company in the State of Maryland dated as of a recent date (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Good Standing Certificate</u></font>&#8221;); and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="zd19ae6cf239c4634a8cba5d9b2298268" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(k)</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">such other documents as we have deemed necessary or appropriate to enable us to express the opinions set forth below.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 1.65pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For purposes of the opinions expressed below, we have assumed (i) the authenticity of all documents submitted to us
      as originals, (ii) the conformity to the originals of all documents submitted as certified or photostatic copies and the authenticity of the originals of such documents, (iii) the legal capacity of natural persons, (iv) the genuineness and validity
      of all signatures, (v) the due authorization, execution and delivery of all documents by all parties and the validity and binding effect and enforceability thereof upon the Company and (vi) the conformity of the documents filed with the Commission
      via the Electronic Data Gathering and Retrieval System, as supplemented by its Interactive Data Electronic Applications system (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>EDGAR</u></font>&#8221;), except for required
      EDGAR formatting changes, to physical copies of the documents prepared by the Company and submitted for our examination.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 1.65pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Based upon the foregoing, and having regard for such legal considerations as we have considered necessary for
      purposes hereof, we are of the opinion that:</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z07d840e150934dcba1c7daf229e08b38" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the Company is a corporation validly existing under the laws of the State of Maryland and is in good standing with the SDAT, and has the requisite corporate power to
              issue the Shares; and</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z3901aa5b27c9483780c0c22adfc67de0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the Shares have been duly authorized and, when and to the extent issued against payment therefor in accordance with the terms of the Underwriting Agreement, the
              Resolutions, the Registration Statement and the Prospectus, will be validly issued and fully paid and non-assessable.</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The opinion in paragraph 1 with respect to existence and good standing of the Company is based solely on the Good Standing Certificate.&#160;
      In expressing the opinions above, we have assumed (i) that the Shares will not be issued or sold in violation of Article VII of the Charter and (ii) that, upon issuance of the Shares, the total number of shares of Common Stock issued and outstanding
      will not exceed the total number of shares of Common Stock that the Company is then authorized to issue under the Charter.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">CareTrust REIT, Inc.</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">November 1, 2024</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Page 3</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The opinions expressed above are subject to the following assumptions, exceptions, qualifications and limitations:</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(A)</font></div>
    <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 36pt; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We have made no investigation of, and we express no opinion as to, the laws of any jurisdiction other than the laws of the State of Maryland. This opinion letter concerns only the effect of the laws (exclusive of the principles of
        conflict of laws) of the State of Maryland as currently in effect.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(B)</font>
      <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 36pt; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We express no opinion as to compliance with the securities (or &#8220;blue
          sky&#8221;) laws of any jurisdiction or as to federal or state tax laws or laws regarding fraudulent transfers.</font></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(C)</font>
      <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 36pt; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The foregoing opinions are rendered as of the date hereof. We assume
          no obligation to update such opinions to reflect any facts or circumstances that may hereafter come to our attention or changes in the law that may hereafter occur.</font></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(D)</font></div>
    <div style="margin: -16px 0px 0px; padding: 0px 0px 0px 36pt; text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">This opinion letter is limited to the matters set forth herein, and no other opinion should be inferred beyond the matters expressly stated.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 0.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We hereby consent to the filing of this opinion letter as Exhibit 5.1 to the Form 8-K on the date hereof and to the
      use of the name of our firm in the section entitled &#8220;Legal Matters&#8221; in the Prospectus. In giving this consent, we do not admit that we are within the category of persons whose consent is required by Section 7 of the Securities Act or the rules and
      regulations promulgated thereunder by the Commission.</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z6dde0abdf9794f19a4bbe013515e3cd2" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Very truly yours,</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">DLA Piper LLP (US)</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ DLA Piper LLP (US)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ctre-20241101.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.9.1.5252 Broadridge-->
<xs:schema targetNamespace="http://caretrustreit.com/20241101" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:ctre="http://caretrustreit.com/20241101" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="ctre-20241101_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ctre-20241101_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://caretrustreit.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>ctre-20241101_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.9.1.5252 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications" xml:lang="en-US" id="dei_WrittenCommunications">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications" xlink:title="label: WrittenCommunications to dei_WrittenCommunications" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial" xml:lang="en-US" id="dei_SolicitingMaterial">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer" xml:lang="en-US" id="dei_PreCommencementTenderOffer">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3" xml:lang="en-US" id="dei_EntityAddressAddressLine3">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry" xml:lang="en-US" id="dei_EntityAddressCountry">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag" xml:lang="en-US" id="dei_NoTradingSymbolFlag">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>ctre-20241101_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.9.1.5252 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://caretrustreit.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="ctre-20241101.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://caretrustreit.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ny20037824x3_logo.jpg
<TEXT>
begin 644 ny20037824x3_logo.jpg
M_]C_X  02D9)1@ ! 0$ E@"5  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !M +P# 2(  A$! Q$!_\0
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M90G&4)P\0N$(SA*+C*,H\0X!2C*+LXRBTTTTFFK/4_NGHHHK_'P_W6"BBB@
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>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45325628602256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  01,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CareTrust REIT, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001590717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-3999490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">905 Calle Amanecer, Suite 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Clemente<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">542-3130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MH-T ?+]6RKYWW"VHNL1.O@-02P,$%     @ PH!A69^@&_"Q @  X@P   T
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
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MOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ P8!A60=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #!
M@&%9!>E^)>X    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    " #!@&%9F5R<(Q &  "<)P  $P
M@ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,& 85DTJU3&
M[P,  - .   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    " #"@&%9GZ ;\+$"  #B#   #0
M@ $R#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ,* 85F7BKL<P    !,"
M   +              "  0X/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ,*
M85D<.&7J/P$  #P"   /              "  ?</  !X;"]W;W)K8F]O:RYX
M;6Q02P$"% ,4    " #"@&%9)!Z;HJT   #X 0  &@              @ %C
M$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #"@&%9
M99!YDAD!  #/ P  $P              @ %($@  6T-O;G1E;G1?5'EP97-=
:+GAM;%!+!08     "0 ) #X"  "2$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>19</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ny20037824x3_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://caretrustreit.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ctre-20241101.xsd</File>
    <File>ctre-20241101_lab.xml</File>
    <File>ctre-20241101_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ny20037824x3_8k.htm">ny20037824x3_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="19">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ny20037824x3_8k.htm": {
   "nsprefix": "ctre",
   "nsuri": "http://caretrustreit.com/20241101",
   "dts": {
    "schema": {
     "local": [
      "ctre-20241101.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ctre-20241101_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ctre-20241101_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ny20037824x3_8k.htm"
     ]
    }
   },
   "keyStandard": 19,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 26,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 19
   },
   "report": {
    "R1": {
     "role": "http://caretrustreit.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20241101to20241101",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20037824x3_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241101to20241101",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ny20037824x3_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://caretrustreit.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001140361-24-045002-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-24-045002-xbrl.zip
M4$L#!!0    ( ,* 85G$Q+O<1@,  $@/   1    8W1R92TR,#(T,3$P,2YX
M<V2U5UMOTS 4?D?B/YB\.Y>F1;1:-X&VH4F#H0$2;\AU3EN+Q FVL[;_'MNI
MT_1*T\";8Y_OXN-S7/?J9IFEZ 6$9#D?>Y$?>@@XS1/&9V.OE)A(RIAW<_WZ
MU=4;C#\"!T$4)&BR0A]$3A+!DAF@+\]/4Y8"ZO7]H1_Y@]Z@UUC&V,"7<B3I
M'#*"%!$S4)])!K(@%,;>7*EB% 24"%"BE$H 4S[-LZ 7]OI1%$;:5 H9<'6?
MB^P6IJ1,U=C[79*431DD'M*[X'*TE#778K'P%[&?BYDF":/@QZ?'KU;=Q5*M
M<I9R%9XR_FN+?#D1J:./ [,\(1)J)WOQ:S/1<#@,[&H=JHG8"6K&I2*<0C,^
M436@&3P(JD47F@#;CI- _5G^$N@%L\.X#E0"JU4!\K /O1R898/IX3#&<9T7
M72+;P"F1$PMR*UM"4JAC\?52!= E@Y I&L)YKHC2]6FGUI-%P?@T7\_H.9/1
MD3N%9Y@BF^.1(1Q[DF5%:A)HY^8"IF//G#]VI_RS$.!KARY$Y"F<.!*S'&B(
MU!5IG3UNA!T%$72/9:\&-$E>@%!,[WI30L$_VU9*)FVWI2&0_M_]&)YO>@?(
M#+X_/YQH0VOI-J>E:?[W/+GCBJG5@SYZD=G,>X@E8^]D1*WN]!.8,LYL187Z
M;@A#A)%C: X)3U!%AQI\5\$NR2Y_*2%YXM=VO%LE:_0ZY!22DI26Z07 C;/C
MN/6L.PG76<%.:U43VPUHVD\77BX4XGM7>+/[9X04Z^:O+O['G%J:*EJZ2^D@
M)H!423=C"CKVES)QM732PY&;[J2'W7 SZ*!*\Y(KL6JCW(2XCRX.2B'T#WD[
M"TU,_=7!!"SIO(V!.MZ..@ASPJALH[P!5,,.VI+1-LHNW S:J>Y>X,/JMN0P
M,R^TP_*[L%2(+10V/#CJX>AM=Q^JM0=UB?YV.E4A6J7?Q=M1MP-HOM7.V;B%
MF"_L<&;[L=E^'%WLHA\(\ZM]I@$;;63[.'R'H[!=UO?>G6>J.H 1'IPM>>QI
MV>'7Q=)T;;OUTTC[HPK#LD@))RH7JWO]?7X+-%GN-B27=$3S3=TJ1RZ^RH]Y
MD;=*S;&W_,7J78_GX!^78V;^AK3?<F/$/HXJLNL_4$L#!!0    ( ,* 85E:
M/R=OT@<  *=.   5    8W1R92TR,#(T,3$P,5]L86(N>&ULS9QM;]LV$,??
M#]AWX+RWLUW;ZX $C8O,;8I@:1(D*?:$89 EQB$FBP&E-,ZW'ZD'VR2/%%.*
MB=XT$N_/._+N1UIF&KU[OUFGZ"MF.:'9T6 R>C- .(MI0K+5T> A'T9Y3,C@
M_?S[[][],!Q^PAEF48$3M'Q"OS(:)8PD*XPNKRYN28K1].?1P6@R>CM].]TS
M#X>B>TJR_P[%/\LHQXB'S?+#34Z.!G=%<7\X'C\^/HX>9R/*5N/IFS>3\1^?
MSZ[C.[R.AB3+BRB+\0!Q_6%>-I[1."K*,>]UWRQ9VCB8C;>QC IQ-VQD0]$T
MG$R'L\EHDR>#>HC"[!"DD6\T?3VGR<'!P;BT;J7<$;&XWDZ;9P^A*G^,IO@*
MWR+Q\\O5J;'WP5@HQADNSJ(E3GG(LGOQ=(^/!CE9WZ>X:;MC^!;VDS*V=2.R
M<R"R,_E%9.?'G>>QS_!6 J8;6D1I-^,L_>ECU<+X#_J\J]3:AGS>99;Y(L<O
MD.6],/Z#OL2,T.1CEH0?N!JJJ\%?%Q%[ 53T8/X3"#]J8*BI:#KC5U)<O"EP
MEN"DB2Q\6_;.,G2YV9:>M[YI+'E-Q:<(9?IT<NZU])CC>+2B7\<))MSS="8N
MAN*BG 6_^7=!^<?G\3(O6!07C:=R$D<#T%:00HQ=L8WE@8K^TE 9SND#B[$2
MP3@"IP1)]:V&!3E<ISR<>"# V?#+]0"1!-+-RUOT=]/PS[OQ;J3Z[(Z97(N(
MQ<U0^&7+\&O%.*;\ _*^&$HSN65T;<H]M:2LSD#IZQ!)$E10!/0;!Z?K XT?
MUC@K;KA'I?20J9Z";/) "XKA0Y;BSP26))LW=TC<OBY48,ZI.5<R4ON*ABAK
MJ0( ]3LC!=]*%W2]?LA(]1"=*Y6W:NHI&30>K%FC^D!G<FRB#];/ZV8DM[\N
MC_9*48?$RH2"T@95MY('8/::IB0F!?].^ID_-# 2I0H^9D$]/4C@@:HYG@^G
MH%<3I(!XOFM#3>/KXFFI"VW+I RFKFNH="AM "0O&1;K /.IE[NW>#AE%[>W
MF"FXM OKB=J$'JBVQ_=!UNK=A*ZETYS;AO&>$5565)I?%V:'2E+7G,MPF_4-
MY,^ (SSLIWG^@)DS\D8Y##X@[PY_XU@Z7 10#,>EH'?5%T2EZ>^Z,)<;7AUM
M>,!K1.ME6"GM- 58+\<\<B*BGZ312H$2M-5356P>V(-1?!A7'9J EG7S[2T2
M]Z_+*9QY:DF83* D:7"SERS@@< )R>,H_1-'[(2WJ-_@6E3*,8&FZN#$P!"Y
MB\,#W77;.8+:8W>D4%F0,*'2UH_S!5/=J%.2X5,'1:P>0+1!$)SEZ@2[G69
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MLR<,<.^=49?B<?XP1-,N.;7Q=A562C@6%^1_/NY&Y _YGX(?_@=02P,$%
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MCD3L7>O#Z.HL0COPCX@QGK0J]%B436,*J"5IPJ''433O(QE<%#\EM/P) !?
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M_CF/$J[5\_7 XF!]?0@17#,,P*]Y/OS5[%!S=-O2]K#&GFJ1 8UA34]@37C
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MHQB5(,I (W*>,'E:@6319!;G$%2DLRQ>D R"TRQ<R)YEA]0'ZHN8-2V&K)4
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MURBJQM'V)H\O# C#DZ.GSU@8QNQ0-_<XU#03MSQ;CUC[\=TA3VJ08/NN0Y#
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MY,<4=FP,RC@#%0YW6]ZT;-"[?6M <LB4E2>@#DRS"=T%H(0OT&)]=/1X.P_
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M*CH]+3D]9 "S7K<^'-Z#^3B?H3'*3E1T?X9F5)4)C"PUQIMV!- RWL.[4K0
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M#A@KN.>MFG]3%;A.LDOZL]ZZ*C#(4[@X-!YD5_GA\5;7T:=EP95$1Q6-^JA
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M%()<W$JFL80.I1FT<I%/<DX2$EL.7/[E*M*YKE"B(2N7K=I)/B*]91<#VJV
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MZ0PYQ#CSA>&-?]_J_+PG>6^X1&^&S4P2<#",)DM,ULXD[B9QY%#S77PJMT;
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M>!TNBRTT]JT DKZ U*[:8ZN#1QY7*6< W K\SE<O)0OF(UP-NA?)963R0^.
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MWPZ0H^=_+4%T$$@%D8T):;<^C*)3%74E\.KIK.W@= >I)=8K8=H8WJ"%PZU
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MT9P'HJZ)7-*RB-VO&7^]^RTN"Z'Z=H8H#:RUBFK=KQP$H /OJG"'15]^JF
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M-P8L%ENGXWOF3Q]OQ&@=\BJ%S=KC=CW_?)V/X##_I"A<';(A0_J;\<W!?&9
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M#&H@W_SH#'G?*'OZHUN_V%N]VJT.7@JB<(4ZW%844%L.ZN8ZN%MBZA=%!RI
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MI"QKJ<<= B:8!3D,\#UL<!39(+3QY+MJ7J3&X/W-/-+IB7SB^3R-AS[IY5S
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M\A76Y_^K-JLP:[5FY!3U"6I_L2)G\YHWIZ#I3TU_HT(J(;WG[-.*!AYY'!:
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MU$(_X)BD>0M?C%VPJ11.!IV3OWAVE'1?_6KPT FEO6OZN/(C_E,@BJ"V2!3
M]!_Q1+?.&4]D@GFV6)IDA1%PDTA2HE/M2D[#X7R2U6];<XH@RY,,9+?:MB@6
M.4*>)A>>0B0Z*%N$T1LV?B Z!:/A$N!S%*:4"A/*'' F',[FN"8[B=,8;EQI
M6(]6&@GHJN2,)Q"TPGQPM<[C+/6:T7Y?+U'8"Z9!N4$/K_2\E.#VA1.6E0CJ
MG>7+@!'YQ@JM+#*D4G-5'F\I>%$P*UB\:Z7;R@.2*?P9'S<S>&-8XADFTI:W
M[4:@B17EN>DD"4<>K25[.]1J.U K^U'KO,33]4@9PG*)N5M9=K4\I>F,B]PW
M@3!HXED.NYIJ)X,NO\_H(\[^!4-PA@X,S/(GN-^8C.97(%N%FOS.#Q#=3?;8
MO+;)<TPL9K2EL92K[]%H#(SQL(<P*+'AB^-%G94V!0^L957G+*-E36P!Z">#
M&<8!NKB5=*==K+2$RQ&NX7-J;B9IG?1DCZ Q,'1B#^T1[!O%7@DH!V9S7]N-
M$QD$PRDG R8=3@E]F9<'<>X]1P0&\@22@J--G.B/V/:F-_;AHQ9\UD5\)C=8
M1ZE!8 /A$,]R\Q'9)(;BW#D[WQ,[&,G#:$HQD."6 K,)P<UV>2 &RL6<D90B
M75BJ66\[?Y:4 G7*6A9+ )Z60*(RC/4S3<-V_?O]C)L 7'#A2[4NU/%4B1,O
MW(Q$P61&KP:<QVR+1Y^(N1RZ(PP@1%9=.T*4<\%9FCC.+7 4A98#<Y5#AT$A
M_=,VD\@7T#*3\$'U4T7<*D&_D\<5#C'<KSS(<=$)/,N?5X'(CG@R2=8^"G"Q
MG!7R=A5A$CZU4FDBX,()4SVJHA/H5*-(6AR*921:]2;8ZGO-Y+PV<^Y=$><H
M?DS(A:"'!S0)-)D+($B#@0S;1"VFG2ND2$C187PH#^!16^*G=F%_\,MV[;_I
M-[QSQ.Y\\N"F_GUZ!B&_2Z*T:(VIGFTZ/B@?NR6C?N3)-9[5ADI*X;- Z*%G
M4VTC\,!]%K!1F NW2WSRY&&P-R54!=8U0F0<O^-(8P4[J1BAR,YEJF871W"4
MM$+!/@7+&,C9TTAL:* /1%!7$O*5GG(K4 &YLO&8KJ&(K2#?'BVF[/&]=-"*
M R,SN+R(M0!E&M+DX0\V"1SM]L$=(DJHFQR/%O4^+5+Y-V)3%%<EI>,,CP8Q
M"!*ML!D[120@MT[F,(?B+N[GL-:B/I(.%@-(S#R$?G#3 *N,XFM0SY*^<YU;
MF\*(#%OOO@KHF]?2!&*"]Q$J@ ^_U$$:)$^O;7XY+H)XX3<'[+0[7YPQ:$&2
MS$"/(PTCR<=22HT[%1&ZN,>98"_Z 2A#C&:#_PGER'&+R@3$":,7?$@@5H1.
M/;E"TD,VDX376EQB)A)SS&%T&EQAR54BPH_2O0G,%%B@ C>W[O!BF(=16?CV
M'$W<U4PGDK3D%D9B,1\6&8WS& +Q7 ERND8+3*<B><1S>]J8W8CL'8P\A#V(
MN?8(74MNFKZX2U^AL" /-RG$]$>QRR,_F FB_">-$N<[4>8_,80+5J>-)^A@
M<P<^+&=8%_/AO-+/63@3T!47XQ1'^>/1@@A+&5*I'Q.88U\&@RN8R02ECI92
M7PP%67Z,+N$Y!HO;,@R8SO%.^@.*PQ2WEVB &*Y;X'+H,U I[-J"&%\,A::8
M"'ZK#DLR0B6;C7*G+UIP^Q*^)1[XBQ@II<C(6,2#)6V$J :\2,2>H0L<CT9V
MJ-F^<Q<WQ%ZA#0=)R($0]?QH=HC6RT.TE/[\<CXHO0K%NI>G\.\/=GH^N/YV
MTZNPDXON^5=VU6<G5Y<W_:L_>_W!#];MGP_.+S^S;Y>G\#;\V.]==&]ZI^SF
MBA']E.#@2_?B@AWWV&=\]Q*>.?Y!K0"]P4W_&WQQ?LFZ)R=7_=/NY4F/?3^_
M^0)$>NRB^WV U[;P\^ &R.,?E[WOV6GZ<=7_8UXER1#U=#.<H4LUP7.T8<Y'
MTG0V#\"(P/A&H;MA#:1;JT&AF<D17V;I2Y7Y3[ Y0\LQ];@$4+\(4,%?R;VB
M 44KN;Y)1H;T3H]]$?H)#W[EWAB3@WN)MOE6'53Q B89C/F09J"?8.X#/T;%
MY"4/ZPVOO!%K:2WK[5IG:#7JP\-FIW78;APUAHUF8UAK6D;SJ-E\RVDMUTNB
MFZ'TB$3R?Z(M#>X5"#CL+F"G_;J<)!M,W/T@-]9*8_Y4^48V,.//GBJ\O.57
MR;5-Y>G>%-NR6_@N2<H+-:U6NNY^_,CK[BND/R_NREQ"]/)]FCI^+>!0-&]Z
M/VTSCNQ2[R3$L7V0B=+7N0E=K\IL8L=5=L)=%^R7HFS-#Q-J@*7$P4-D7ZML
M *[HO6/>KD.G667?'>@'GR"E[QS,RK7ZTT++C7L<J5R PSI:ATB[RKK@JK(K
M-US+]_K4 69,\5)-P#Y7V;4;3XQUR!Q4";MU8#BG"7^*+O?G-5?VD=Q?9<UJ
M2J)HU6=V_H*EG_V]*%E$)M47CR,_^2H0S8GOA [ZP/!B0#P!W>'9H$*(%FA6
MHK58HZ2?Q+__^YOA6[-/^&$<35SX\!]02P,$%     @ PH!A6=]1P+J6$@
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MVW#M-NRGXU?X8WOJ@_GAP/\#4$L! A0#%     @ PH!A6<3$N]Q& P  2 \
M !$              ( !     &-T<F4M,C R-#$Q,#$N>'-D4$L! A0#%
M  @ PH!A65H_)V_2!P  ITX  !4              ( !=0,  &-T<F4M,C R
M-#$Q,#%?;&%B+GAM;%!+ 0(4 Q0    ( ,* 85D0 (T<A@4  '0Y   5
M          "  7H+  !C=')E+3(P,C0Q,3 Q7W!R92YX;6Q02P$"% ,4
M" #"@&%9&@E?U<X2  "46@  $P              @ $S$0  ;GDR,# S-S@R
M-'@S7SAK+FAT;5!+ 0(4 Q0    ( ,* 85F"X,##^I$  %XP P 6
M      "  3(D  !N>3(P,#,W.#(T>#-?97@Q+3$N:'1M4$L! A0#%     @
MPH!A6=]1P+J6$@  07   !8              ( !8+8  &YY,C P,S<X,C1X
A,U]E>#4M,2YH=&U02P4&      8 !@". 0  *LD

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>ny20037824x3_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ctre-20241101.xsd" xlink:type="simple"/>
    <context id="c20241101to20241101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001590717</identifier>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20241101to20241101"
      id="Fact_31b09ac29ee1449bac9eb18b3aed7886">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20241101to20241101"
      id="Fact_680836d141464ccc9dca32a67360f7fa">0001590717</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20241101to20241101"
      id="Fact_e8fd34e8c96c42969f0306d65901ee92">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20241101to20241101"
      id="Fact_0d1d9ec8bf084d3993f2a8f8554ebeec">2024-11-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20241101to20241101"
      id="Fact_24e77630533e492c9aabd50f65d79fe4">CareTrust REIT, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20241101to20241101"
      id="Fact_3ceaf2d26215402095386bf76e0f5f8c">MD</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20241101to20241101"
      id="Fact_677016bf31674dda9e53876e93777ccb">001-36181</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20241101to20241101"
      id="Fact_ab7bb32702b640f6b01d9cc304ce8150">46-3999490</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20241101to20241101"
      id="Fact_ec5e9ccb6e084fcda99b4fc16f172651">905 Calle Amanecer, Suite 300</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20241101to20241101"
      id="Fact_c7a260357a0b4a85af732675c01a1725">San Clemente</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20241101to20241101"
      id="Fact_3fe86d86a05845bea564201fe442865e">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20241101to20241101"
      id="Fact_523407974eeb46b9b689e98a1a3b33e5">92673</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20241101to20241101"
      id="Fact_f691b477e085408bb6605bf6523e7625">949</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20241101to20241101"
      id="Fact_d457f46c1a514b2e843ccee5b400d2bc">542-3130</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20241101to20241101"
      id="Fact_b0f11ea7bd49431fa36ff095322712c1">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20241101to20241101"
      id="Fact_4bd75bfe8163423984ab07e8a0d060e4">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20241101to20241101"
      id="Fact_9cec7e15227d4e999228733237a0552b">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20241101to20241101"
      id="Fact_3782d26850264e539124a89f758d1be5">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20241101to20241101"
      id="Fact_58e3f164eac24571895bdf41f8080fd0">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
